    
   i 
INTERVENTION STUDY ( CLINICAL TRIALS ) 
  
Title:  Feasibility Study for the  Randomized Pragmatic Pediatric 
Trial of Balanced versus Normal Saline Fluid in Sepsis  
Short Title  PRoMPT BOLUS - Feasibility  
Drug or Device 
Name(s):  0.9% Isotonic (“Normal”) Saline, Lactated Ringer’s  
FDA IND  136978  
Regulatory Sponsor:  FDA  
eIRB Number   17-013936  
Protocol Date:   November 6, 2017  
Amendment 1 Date:  Amendment 3 Date:  
Amendment 2 Date:  Amendment 4 Date:  
 
IND Sponsor   
Scott L. Weiss, MD  MSCE  
Assistant Professor of A nesthesia, Critical Care, and Pediatrics  
Perelman School of Medicine at the University of Pennsylvania  
Attending Physician, Division of Critical Care  
Department of Anesthesia and Critical Care Medicine  
Children’s Hospi[INVESTIGATOR_6684]  
[ADDRESS_776286]., 7S Tower , Room 7C04  
Philadelphia, PA, [ZIP_CODE]  
Phone:  215 -590-2356  
Email: [EMAIL_11226]  
 
Study Principal Investigator:  
[INVESTIGATOR_589367], MD PhD MSCE  
Assistant Professor of Pediatrics  
Perelman School of Medicine at the University of Pennsylvania  
Attending  Physician, Division of Emergency Medicine  
Children’s Hospi[INVESTIGATOR_6684]  
[ADDRESS_776287], Office 1516  
Phone: [PHONE_12234]  
Email: [EMAIL_11227]  
 
    
   ii 
 
Table of Contents  
Abbreviations and Definitions of Terms ................................ ................................ ..............  v 
Abstract  ................................ ................................ ................................ ................................ . vi 
Protocol Synopsis  ................................ ................................ ................................ .................  vii 
Table 1: Schedule of Study Procedures  ................................ ................................ .............  xii 
Figure 1:  Pi[INVESTIGATOR_589368]  ................................ ................................ ..........................  xiii 
[ADDRESS_776288] OR INTERVENTION  ................................ ..... 2 
1.3 FINDINGS FROM NON-CLINICAL AND CLINICAL STUDIES  ................................ ................................ ..... 3 
1.3.1  Pre-Clinical Studies  ................................ ................................ ................................ ........................  3 
1.3.2  Clinical Studies  ................................ ................................ ................................ ...............................  3 
1.4 SELECTION OF DRUGS AND DOSAGES ................................ ................................ ................................ ... 5 
1.5 RELEVANT LITERATURE AND DATA ................................ ................................ ................................ ..... 7 
1.6 COMPLIANCE STATEMENT  ................................ ................................ ................................ ....................  8 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ............................  10 
2.1 PRIMARY OBJECTIVE (OR AIM) ................................ ................................ ................................ ..........  10 
2.2 SECONDARY OBJECTIVES (OR AIM) ................................ ................................ ................................ .... 10 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................................ ..................  11 
3.1 GENERAL SCHEMA OF STUDY DESIGN  ................................ ................................ ...............................  11 
3.1.1  Screening Phase  ................................ ................................ ................................ ............................  11 
3.1.2  Interve ntion Phase  ................................ ................................ ................................ ........................  11 
3.1.3  Follow -up Phase  ................................ ................................ ................................ ...........................  12 
3.2 ALLOCATION TO TREATMENT GROUPS AND BLINDING  ................................ ................................ ...... 13 
3.3 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES ................................ ................................ . 13 
3.3.1  Duration of Study Participation  ................................ ................................ ................................ .... 13 
3.3.2  Total Number of Study Sites/Total Number of Subjects Projected  ................................ ................  [ADDRESS_776289] COMPLETION /WITHDRAWAL  ................................ ................................ ...............................  [ADDRESS_776290] Review  ................................ ................................ ................................ .................  22 
5.1.2  Laboratory Evaluations ................................ ................................ ................................ .................  23 
5.1.3  Radiographic Evaluations  ................................ ................................ ................................ .............  23 
5.2 FEASIBILITY EVALUATIONS  ................................ ................................ ................................ ................  24 
5.2.1  Aim 1  ................................ ................................ ................................ ................................ .............  24 
5.2.2  Aim 2  ................................ ................................ ................................ ................................ .............  24 
5.2.3  Aim 3  ................................ ................................ ................................ ................................ .............  24 
    
   iii 
5.3 EFFICACY EVALUATION  ................................ ................................ ................................ .....................  25 
5.4 SAFETY EVALUATION  ................................ ................................ ................................ .........................  25 
6 STATISTICAL CONSIDER ATIONS  ................................ ................................ ................................ .... 27 
6.1 PRIMARY ENDPOINT  ................................ ................................ ................................ ...........................  27 
6.2 SECONDARY ENDPOINTS  ................................ ................................ ................................ ....................  27 
6.3 STATISTICAL METHODS ................................ ................................ ................................ ......................  27 
6.3.1  Baseline Data  ................................ ................................ ................................ ................................  27 
6.3.2  Feasibility Analysis  ................................ ................................ ................................ .......................  27 
6.3.3  Efficacy Analysis  ................................ ................................ ................................ ...........................  28 
6.3.4  Safety Analysis  ................................ ................................ ................................ ..............................  28 
6.4 SAMPLE SIZE AND POWER  ................................ ................................ ................................ ..................  28 
6.5 INTERIM ANALYSIS  ................................ ................................ ................................ ............................  29 
7 STUDY MEDICATION ................................ ................................ ................................ ...........................  30 
7.1 DESCRIPTION  ................................ ................................ ................................ ................................ ...... 30 
7.1.1  Packaging  ................................ ................................ ................................ ................................ ...... 30 
7.1.2  Labeling  ................................ ................................ ................................ ................................ ........  30 
7.1.3  Dosing  ................................ ................................ ................................ ................................ ...........  30 
7.1.4  Trea tment Compliance and Adherence  ................................ ................................ .........................  30 
7.1.5  Drug Accountability  ................................ ................................ ................................ ......................  31 
8 SAFETY MANAGEMENT  ................................ ................................ ................................ .....................  32 
8.1 CLINICAL ADVERSE EVENTS  ................................ ................................ ................................ ..............  32 
8.2 ADVERSE EVENT REPORTING  ................................ ................................ ................................ .............  32 
8.3 DEFINITION OF AN ADVERSE EVENT  ................................ ................................ ................................ .. 33 
8.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)  ................................ ................................ ...........  33 
8.4.1  Relationship of SAE to study drug or other intervention  ................................ ...............................  34 
8.5 IRB/IEC  NOTIFICATION OF SAE S AND OTHER UNANTICIPATED PROBLEMS  ................................ ...... [ADDRESS_776291] (DSMB)  ................................ ................................ ........................  39 
9.4.3  Risk Assessment  ................................ ................................ ................................ .............................  40 
9.4.4 Potential Benefits of Trial Participation  ................................ ................................ .......................  42 
9.4.5  Risk-Benefit Assessment  ................................ ................................ ................................ ................  42 
9.5 RECRUITMENT STRATEGY  ................................ ................................ ................................ ..................  43 
9.6 INFORMED CONSENT /ASSENT AND HIPAA  AUTHORIZATION  ................................ ............................  43 
9.6.1  Informed Consent and HIPAA Authorization  ................................ ................................ ................  43 
9.6.2  Waiver of Assent  ................................ ................................ ................................ ............................  44 
9.6.3  Exception From Informed Consent (EFIC)  ................................ ................................ ...................  44 
9.6.4  Non-Engli sh Speakers  ................................ ................................ ................................ ...................  47 
9.7 PAYMENT TO SUBJECTS /FAMILIES  ................................ ................................ ................................ ..... 48 
10 PUBLICATION  ................................ ................................ ................................ ................................ ........  49 
    
   iv 
11 REFERENCES  ................................ ................................ ................................ ................................ .........  50 
Appendix  ................................ ................................ ................................ ...............................  54 
 
  
    
   v 
ABBR EVIATIONS AND DEFINI TIONS OF TERMS  
C 
95% CI  
ACCM   Degrees centigrade  
95% confidence interval  
American College of Critical Care Medicine  
AE 
AKI 
CHOP  
CRF  
DCC  
DKA  
DSMB  
ED 
EFIC  
FDA  
HIPAA  
ICD-[ADDRESS_776292]  
RRT  
SAE  
SAN  
SID 
tPA  Adverse Event  
Acute Kidney Injury  
Children’s Hospi[INVESTIGATOR_589369] d Drug Administration  
Health In surance Portability and Accountability Act  
International Classification of Diseases, 9th edition  
International Conference on Harmonization  
Investigational New Drug  
Intraosseus  
Institutional Review Board  
Intravenous  
Kilogram  
Legally Authorized Representative  
Lactated Ringers  
Milliliter  
Sodium Chloride  
Normal Saline  
Non Steroidal Anti Inflammatory Drug  
Odds Ratio  
Pediatric Emergency Care Applied Research Network  
Personal Health Information  
Pediatric Health Information System  
Pediatric Intensive Care Unit  
Randomized Controlled Trial  
Renal Replacement Therapy  
Serious Adverse Event  
Storage Area Network  
Strong Ion Difference  
Tissue Plasminogen Activator  
    
   vi 
ABSTRACT  
Context :  Intravenous (IV) crystalloids are the standard resuscitative  fluid for pediatric 
septic shock.  Despi[INVESTIGATOR_589370] -buffered 0.9% “normal” saline 
(NS) and buffered/balanced lactated Ringer’s (LR) to restore effective circulation and 
increasing data supporting relative benefits and improved safety profile for LR over NS, the 
use of NS overwhelmingly remains the most commonly used crystalloid fluid in pediatric 
septic shock.  A cost -efficient approach to definitively determine the comparative 
effectiveness and safety of NS and LR is with a lar ge pragmatic randomized trial, though 
concerns regarding feasibility need to be addressed prior to such a trial.  
Objectives : The objective of this study is to assess overall feasibility of this study at CHOP 
with the following specific aims : 
Aim 1:  To det ermine compliance with study fluid administration, throughout the 
intervention phase, within each randomized arm using a pragmatic study design  
Aim 2:  To estimate  the proportion of eligible pediatric patients with suspected septic shock 
who may be enrolle d into a randomized pragmatic trial of fluid resuscitation  
Aim 3:  To demonstrate feasibility  of patient enrollment into a pragmatic fluid resuscitation 
trial using Exception from Informed Consent (EFIC)  
Study Design : Randomized , controlled , open -label  pragmatic pi[INVESTIGATOR_589371]/Participants:   Eligible patients > 6 months and <[ADDRESS_776293] 20 ml/k g of fluid resuscitation will be enrolled in the 
Emergency Department of the Children’s Hospi[INVESTIGATOR_589372].  Patients will be enrolled 
prior to receipt of > 40 mL/kg IV/IO crystalloid fluid .  Due to the life -threatening nature of 
septic shock and the narrow therapeutic window for fluid resuscitation, potential subjects 
will be enrolled through the feder al “exception from informed consent” (EFIC) process , with 
prospective  informed consent obtained as possible  in rare circumstances .  
Study Interventions and Measures :  Seventy subjects will be randomized to receive either 
open -label NS or LR for all remaini ng fluid administration (bolus and maintenance) until 
11:59pm on the calendar day following randomization such that all patients receive a t least 
[ADDRESS_776294] study fluid within each 
randomized arm  (Aim 1). Secondary outcomes will include mean proportion of total 
crystalloids administered as non -study fluid in each arm (Aim 1), percent 
enrollment/randomization/treatment of eligible patients (Aim 2), and successful EFIC 
approval with <10% subject withdrawal.  Specified s afety outcomes  will be monitored as 
they occur in the course of routine clinical practice but this pi[INVESTIGATOR_589373] t hat both fluids are FDA -approved and have well -described efficacy 
and safety profiles.  
    
   vii 
PROTOCOL SYNOPSIS  
Study Title  Feasibility Study for the  Randomized Pragmatic Pediatric Trial 
of Balanced versus Normal Saline Fluid in Sepsis  (PRoMPT 
BOLUS – Feasibilit y) 
Funder  The Children’s Hospi[INVESTIGATOR_589374] /feasibility  study  
Study Rationale  Intravenous (IV) crystalloids are the standard resuscitative fluid for 
pediatric septic shock.  Despi[INVESTIGATOR_589370] -
buffere d 0.9% “normal” saline (NS) and buffered/balanced lactated 
Ringer’s (LR) to restore effective circulation and increasing data 
supporting relative benefits and improved safety profile for LR over 
NS, the use of NS overwhelmingly remains the most commonly 
used crystalloid fluid in pediatric septic shock.  A cost -efficient 
approach to definitively determine the comparative effectiveness 
and safety of NS and LR is with a large pragmatic randomized trial, 
though concerns regarding feasibility need to be addresse d prior to 
such a trial.  The objective of this pi[INVESTIGATOR_589375] a larger randomized pragmatic trial 
comparing the clinical effe ctiveness of fluid resuscitation  with NS 
versus LR for pediatric patients with  suspected  septic shock .  
Necessary feasibility assessments include ensuring appropriate 
compliance with study fluid in each of the two arms, effectiveness 
of study enrollment using a pragmatic study design embedded 
within routine clinical practice, and ac ceptability of using Exception 
from Informed Consent (EFIC) .  
Study Objective( s) Primary   
 To determine compliance with study fluid administration, 
throughout the intervention phase, within each randomized arm 
using a pragmatic study design . 
Secondary  
 To estimate the proportion of eligible pediatric patients with 
suspected septic shock who may be  enrolled into a randomized 
pragmatic trial of fluid resuscitation . 
 To demonstrate  feasibility  of patient enrollment into a pragmatic 
fluid resuscitation trial usin g Exception from Informed Consent  
(EFIC).  
Test Article( s)  Study arm #1:  Fluid resuscitation with lactated Ringer’s (LR)  
 Study arm #2   Fluid resuscitation with 0.9% “normal” saline 
(NS)  
    
   viii 
Study Design  
 Randomized, open -label pragmatic pi[INVESTIGATOR_589376] . 
Subject Population  
key criteria for 
Inclusion and 
Exclusion:  Inclusion Criteria  
1. Age >6 months to <18  years  
2. Clinician concern for septic shock, operatio nalized as:  
a. a “positive” ED sepsis alert confirmed at the 
physician led “sepsis huddle” OR  
b. a physician diagnosis of suspected septic shock 
requiring parenteral antibiotics and fluid resuscitation 
as per the ED sepsis management pathway  
Condition 2a above i s met by:  
A. Tachycardia or hypotension for age AND  
B. Fever (home or ED >38 °F), hypothermia, or other 
signs/symptoms of infection AND  
 
At least one of C, D, or E  
 
C. Flash (< 1 second) or delayed (>3 seconds) capi[INVESTIGATOR_308425]  
D. Altered mental status  
E. Existing high -risk condition, including:  
i. <[ADDRESS_776295] 20 mL/kg IV/IO fluid resuscitation  
4. Receipt of ≤ 40 mL/kg IV/IO crystalloid fluid prior to 
randomization  
5. Additional fluid deemed likely to be necessary to treat poor 
perfusion, defined as either hypotension for age or abnormal 
capi[INVESTIGATOR_39093] (as determined by [CONTACT_30223]’s judgment)  
6. Parental/guardian permission (informed consent) if time 
permits; otherwise, EFIC criteria met  
    
   ix 
Exclusion Criteria :  
1.   Clinician judgement that patient’s condition deems it unsafe 
to administer either NS or LR (sinc e patients will be equally 
likely to receive NS or LR at time of study enrollment), 
including (but not limited to):  
a) Clinical suspi[INVESTIGATOR_589377]  
b) Known hyp erkalemia, defined as non -hemolyzed whole 
blood or plasma/serum potassium > 6 mEq/L, based on data 
available at or before patient meets criteria for study 
enrollment  
c) Known hypercalcemia, defined as plasma/serum total 
calcium >12 mg/dL or whole blood ionize d calcium > 1.35 
mmol/L, based on data available at or before patient meets 
criteria for study enrollment  
d) Known acute fulminant hepatic failure, defined as 
plasma/serum ALT >10,000 U/L or total bilirubin >12.0 
mg/dL,  based on data available at or before pa tient meets 
criteria for study enrollment  
e) Known history of severe hepatic impairment, defined as 
diagnosis of cirrhosis, “liver failure”, or active listing for 
liver transplant  
f)   Known history of severe renal impairment, defined as current 
dependency on pe ritoneal dialysis or hemodialysis  
g) Known metabolic disorder, inborn error of metabolism, or 
primary mineralcorticoid deficiency (e.g., mitochondrial 
disorder, urea cycle disorder, amino acidemia, fatty acid 
oxidation disorder, glycogen storage disorder, con genital 
adrenal hypoplasia, Addison’s disease) as reported by 
[CONTACT_1130], LAR or accompanying caregiver, or as listed in the 
medical record  
 
2.    Known pregnancy  
3. Known prisoner as determined by [CONTACT_589419]/or LAR (or other ac companying 
acquaintance)  
4. Known allergy to either normal saline or lactated Ringer’s as 
determined by [CONTACT_589420]/or LAR (or other accompanying acquaintance) or as 
indicated in the medical record  
    
   x 
5. Indication of prior decl ined consent to participate based on 
presence of  a “PRoMPT BOLUS Opt -Out” bracelet  with 
appropriate messaging embossed into the bracelet or opt -out 
letter that will be provided to the family to be presented to 
clinical team at time of care  
Number Of Subje cts  
 Total Number of Subjects  = 80 
Total Number at CHOP = 80 
Total Number of Sites  = [ADDRESS_776296]’s participation will last up to 90 days, including 1 day 
for screening, 1 -2 days for study intervention, and up to 90 days for 
follow -up. 
 
Study Phases  
Screening  
Study Treatment  
Follow -Up   (1) Screening : screening for el igibility and obtaining 
consent/EFIC  
(2) Intervention  phase : use of randomized crystalloid fluid (NS 
or LR) for resuscitation and maintenance fluid  
(3) Follow -up: determination of stud y completion or subject 
withdrawal, including vital status and clinical outcome 
assessment at hospi[INVESTIGATOR_53767] [ADDRESS_776297]  
Efficacy Evaluations  Feasibility will be assessed as part of each aim as follows:  
 Aim 1:  proportion of total crystalloids administered as 
saline  in each arm (primary) and proportion of total 
crystalloids administered as non -study fluid (i.e., cross -over) 
in each arm (secondary)  
 Aim 2:  percent enrollment/randomization/treatment of 
eligible patients  
 Aim 3: successful EFIC approval with ≤10% subject 
withdrawal  
Efficacy outcomes, including mortality, hospi[INVESTIGATOR_307] -free days, dialysis, 
and length of stay, will be collected in preparation for a subsequent 
multicenter trial, though this pi[INVESTIGATOR_589378].  
Safety Evaluations  For this single -site feasibility  study, specified safety outcomes will 
be monitored as they occur in the course of routine clinical practice 
but this feasibility  study will not be powered to assess safety given 
that both flui ds are FDA -approved and have well -described efficacy 
and safety profiles.  
Statistical And 
Analytic Plan  The statistical plan will be descriptive for this feasibility study.  
    
   xi 
For Aim 1, feasibility will be defined by [CONTACT_5640]:  
1) an absolute difference in the me an use of NS between study 
arms of at least  65% with a lower 95% CI border of >60%, 
or 
2) at least 85% of subjects in the NS arm receiving ≥90% of 
study fluid as NS during the study window and at least 80% 
of subjects  in the LR arm receiving ≥75% of study flu id as 
LR. 
The secondary endpoints will be defined as meeting feasibility 
criteria if:  
 The proportion of eligible patients treated in the pediatric 
ED who are enrolled, randomized, and treated with study 
fluid is >65%.  
 EFIC is approved by [CONTACT_589421]  
 The proportion of eligible patients who meet criteria for 
EFIC who are not enrolled or who are enrolled but withdraw 
prior to completion of the follow -up phase is ≤10%.  
Data and Safety 
Monitoring Plan  Data will be managed and stored by [CONTACT_589422].  In addition the PI, an independent Data Safety 
Monitoring Board (DSMB) will be convened to ensure data quality 
and patient safety.  
 xii   
   
TABLE 1: SCHEDULE OF  STUDY PROCEDURES  
Study Phase  Screening  Intervention  Follow -Up1 
Study D ay 1 1 2 2 to 902 
Informed Consent/Assent  or EFIC  X    
Review Inclusion/Exclusion Criteria  X X X X 
Inform patient/LAR of study 
enrolment (if EFIC)   X X X 
Demographics/Medical History  X   X 
Prior/Concomitant Medications  X X X X 
Randomization  X    
Dispense Study Drug   X X  
Drug Compliance   X X  
Open -label fluid treatment     X 
Data collection    X X X 
Outcome Assessment:  Aim 1    X  
Outcome Assessment:  Aim 2  X    
Outcome Assessment:  Aim [ADDRESS_776298]  
 page xiii   
FIGURE 1:  PI[INVESTIGATOR_589379] M  
 
 
 
 
.

   1 
1 BACKGROUND INFORMATI ON AND RATIONALE  
1.1 Introduction  
Approximately 5,000 children die from sept ic shock each year in the US and thousands 
more die worldwide.1,2  Despi[INVESTIGATOR_589380], 
contemporary studies still report 2 -6% mortality for children with septic shock treat ed in the 
pediatric  emergency department  (ED).3-7  In our recent  survey of the Pediatric Emergency 
Care Applied Research Network ( PECARN ), 45%  of physicians  had treated a child for 
septic shock in the ED who subseq uently died in the hospi[INVESTIGATOR_589381]  
(unpublished data) . 
 
Fluid resuscitation is the cornerstone of resuscitation  for hypovolemia and shock , and  
intravenous fluids are among the most co mmonly used therapi[INVESTIGATOR_589382] .8,[ADDRESS_776299] appropriate fluid type to restore effective blood volume 
and optimize organ perfusion.  In the absence of a clear role for the early use colloids , 
administration of crystalloid fluids is ge nerally preferred (except in cases of 
hemorrhage ).10,[ADDRESS_776300] resuscitative fluid .12  Crystalloid  fluids can be categorized as non -buffered (most 
commonly 0.9% normal saline [NS]) or buffered/balanced (in the US, this is most 
commonly lactated Ringer’s [LR]) solutions.  NS and LR are inexpensive, stable at room 
temperature, and nearly universally avai lable with identical storage volumes and dosing 
strategies. Notably, both are also of proven clinical benefit in septic shock  and have 
extensive clinical experience for use in fluid resusciation of critically ill patients.8  However, 
while NS is  currently  used in 80 -95% of cases of septic shock ,13-[ADDRESS_776301] demon strated a 1 -4% absolute mortality reduction and up to 
a 50% lower odds of dialysis compared to NS in observational and non -randomized 
interve ntional studies in adult sepsis.16,[ADDRESS_776302] the comparative effectiveness of NS and LR , a well -powered 
randomized controlled trial (RCT) is necessary.  A large pragmatic randomized trial 
embedded within everyday clinical practice provides a cost -efficient and generalizable 
approach  to inform clinicians about best comparative effectiveness of common therapi[INVESTIGATOR_014] .[ADDRESS_776303] 
small effects and simple enough to incorporate into routine clinical practice.  The 
characteris tics of LR and NS provide the ideal scena rio for a large pragmatic trial.18  An ED -
based trial is necessary to enroll patients at initiation of resuscitation.22,23  While any benefit 
is expected to be smal l, even a 1 -2% absolute reduction in mortality that is in line with prior 
adult studies  would be a clinically important difference by [CONTACT_589423] 50 -100 
children in the US (and many more worldwide) each year.  This overall public health impact 
is commensurate with  changing from NS to LR  because such a practice change is  a simple, 
cost-neutral shift from largely using NS to largely using LR . 
   2 
 
However, before embarking on a large, pragmatic randomized trial that will determine the 
comparative effectiv eness and safety of NS and LR , several concerns regarding feasibility  of 
such a trial  need to be  addressed including a) ensuring adequate compliance with study fluid 
administration within each randomized arm using the proposed pragmatic study design, b) 
determining that a sufficient proportion of patients can be enrolled using the proposed  
pragmatic study design that will be embedded within  routine clinical practice  rather than use 
of a dedicated study team , and c) demonstrating that the study can feasibly be performed 
using EFIC when  enroll ing critically ill infants, children, and adolescents into this clinical 
trial.  If these feasibility criteria can be adequately demonstrated at CHOP as a single site, 
we will have established the necessary feasibility me trics to indicate a high likelihood of 
success  in a larger, multicenter study that will enroll several thousand patients across the 18 
sites comprising Pediatric Emergency Care Applied Research Network (PECARN) to test 
morbidity and mortality outcomes.  
1.[ADDRESS_776304] or Intervention  
The study intervention will be the use of lactated Ringer’s (LR), a balanced/buffered 
crystalloid fluid, for initial resuscitation of pediatric patients with suspected septic shock.  
The comparis on group will be use of 0.9% “normal” saline (NS), a non -buffered isotonic 
crystalloid fluid that is most commonly used to resuscitate patients treated for suspected 
septic shock in pediatric emergency departments in the [LOCATION_002].  For example, in the 
PECARN registry of three large, academic pediatric EDs, LR was used in only 0.2% of 
suspected cases of septic shock  (personal communication, Elizabeth Alpern) .  Therefore, 
although LR is commonly cited in the literature, recommended (along with NS) as an 
appropriate crystalloid fluid option for pediatric septic shock, and is used in approximately 
50% of septic shock cases treated in the CHOP PI[INVESTIGATOR_6890], use of LR as an alternative crystalloid 
resuscitative fluid  to NS  in the pediatric ED  setting requires a specif ic interventional study.  
The package inserts for NS is included in Appendix 1 and for LR is included in Appendix 2.   
Table 1 shows the biochemical components of NS and LR.  
Tabl e 1:  Composition of Human Plasma, Normal Saline, and Lactated Ringer’s  
Content1 Human Plasma  0.9% Normal 
Saline  Lactated 
Ringer’s  
Sodium  140 154 130 
Chloride  100 154 109 
Potassium  4 0 4 
Calcium  5 0 2.7 
Magnesium  1.0 0 0 
Lactate  1-2 0 28 
Bicarbonate  24 0 0 
Osmolality (mOsm/L)  [ADDRESS_776305] (US $ per liter)  --  $1.00  – 2.00 $1.00 - $2.00  
1Units are mEq/L (unless indicated)  
   3 
1.3 Findings from Non -Clinical and Clinical Studies  
1.3.1 Pre-Clinical Studies  
NS contains a supra -physiologic concentration of chloride (1.5X that of plasma) and a 
strong ion difference (SID) of zero but is isoto nic compared to extracellular fluid.  LR has 
less chloride, small amounts of additional electrolytes, and a higher SID due to the presence  
of lactates as an anion buffer.8,24  The high chloride content and low SID of NS has been 
associated with acute kidney injury (AKI), acidemia, hyperkalemia, vascular permeability, 
inflammation, coagulopathy, fluid overload, and death.25  For example, infusion of NS 
reduced renal blood flow and the glomerular filtration rate in a dog model to a greater e xtent 
than more balanced fluids.26  In addition, hyperchloremic metabolic acidosis produces a 
more profund pro -inflammatory response in a cell model than other forms of acidemi a, such 
as hyperlactatemia .27  In a rat model of sepsis, fluid resusication with NS resulted in higher 
blood chloride, lower arterial blood pH, a more severe pattern of acute kidney injury, and 
higher lev els of the pro -inflammatory cytokine in terleukin -6.28 
1.3.2 Clinical Studies  
[IP_ADDRESS]  Clinical Studies in Adults  
In healthy human volunteers, infusion of NS impairs renal blood flow compared to LR and 
has demonstrated impaired co gnition that was not evident with sim ilar volumes of balanced 
fluids.29  Moreover, the development of a hyperchloremic metabolic acidosis has been 
associated with mortality after surgery30, adult critical illness,31 and pediatric sepsis (Hector 
Wong, MD, personal communication, February 14, 2017).  
Several studie s have compared the effects of infusions of NS and buffered crystalloids on 
outcomes for adults with sepsis and other critical illnesses.  In a sequential period study of 
critically -ill adults, use of chloride -restrictive fluids reduced AKI by [CONTACT_34120] 50%.17  
However, the SPLIT crossover trial in 2,278 critically -ill adults found no differences in AKI 
or mortality for chlor ide-restrictive versus NS fluid.32  Similarly, in the  CRISTAL open -
label randomized trial of adult ICU patients with hypovolemic shock, 31% of 72 patients 
who received LR died compared to 27% of  1,035 who received NS (p=0.49).[ADDRESS_776306] some crystalloid  fluid as LR was associated with a 
14% relative reduction in hospi[INVESTIGATOR_34380] , with a dose -dependent decrease in mortality as 
proport ion of total crystalloid infused as LR increased .16  In a meta -analysis, adult septic 
patients who received balanced fluids had a trend towards a lower mortality than those that 
received NS (OR 0.78, 95% CI 0.58, 1 .05) although no trial directly  compared NS to 
balanced fluids.[ADDRESS_776307]-operative infections.36 
 
Two ongoing trials are currently comparing b alanced fluids to NS in adult shock (PLUS 
study in septic shock, ClinicalTrials.gov [STUDY_ID_REMOVED] and SaLT -ED study in all shock, 
ClinicalTrials.gov [STUDY_ID_REMOVED]).  However, both trials specifically exclude patients <18 
years of age.  
   4 
[IP_ADDRESS]  Clinical Studies in Child ren 
In pediatric sepsis, t here are limited  data comparing clinical outcomes following LR versus  
NS resuscitation.  While Carcillo et al. demonstrated the importance of early fluid 
resuscitation in pediatric septic shock, there was no differentiation  betwee n use of NS or LR 
in that landmark study.37  In a randomized trial of four fluid regimens in children with 
dengue fever in Vietnam , patients receiving LR required a median of 15 minutes longer  to 
recover from shock compared to NS but this small study was not powered for morbidity or 
mortality outcomes and dengue shock syndro me has unique circulatory and vasogenic 
pathophysiology compared to the more typi[INVESTIGATOR_589383] U.S.38  
In a small randomized study of balanced fluid (sterofundin) versus NS during major surgery 
in children up to 3 years of age conducted in [LOCATION_013], subjects randomized to NS had 
higher blood chloride and more acidemia, but no difference in clinical outcomes.  The theme 
of insufficient power to determine the comparative effectiveness of NS versus LR (or other 
balance d fluids) is common in the pediatric literature.  Unfortunately, t he large st prospective 
study of fluid resuscitation conducted in children with severe infections to date restricted 
crystalloid fluid s only t o NS.[ADDRESS_776308] was a propensity -matched analysis of 2,398 
patients in the Pediatric Health Information Systems ( PHIS) database who received 
exclusive NS - or LR -based fluid resuscitation for septic shock and was presented in abstract 
form at the 2016 Society of Critical Care Medicine Annual Congress.  The authors reported 
a 2% lower mortality for children receiving LR v ersus NS.[ADDRESS_776309] some proportion of LR fluid  from 382 hospi[INVESTIGATOR_589384] r Healthcare Alliance.41  Patients were identified using  International 
Classification of Disease -9-Clinical Modifications  (ICD -9-CM) codes for either severe 
sepsis/septic shock or a combination of codes indicating infection with organ system 
dysfunction.  Overall , we found no difference s in mortality, AKI, or u se of renal 
replacement therapi[INVESTIGATOR_589385],  even when matched by  [CONTACT_589424].  But for the subset of patients identified 
using sepsis -specific ICD -9-CM codes (which we and others ha ve previously shown to have 
more severe illness than patients identified using combination codes), 30 -day hospi[INVESTIGATOR_589386] (13.8%) compared to only NS (16.4%; 
p=0.16), as did the proportion treated with renal rep lacement therapi[INVESTIGATOR_014] ( RRT ): LR, 1.9% 
versus NS, 3.9%; p=0.07).  However, in our cohort,  LR was preferentially used either as 
first-line fluid in patients with lower illness severity  or as an adjunctive fluid in patients who 
received large amount s of fluid re suscitation, and the matching algorithm was least effective 
in the most severely ill patients who received the largest total fluid volumes.  Consequently, 
we concluded that the results of our study are best interpreted as establishing the need for 
and the equipoise to conduct a prospective randomized trial to definitely address the 
comparative effectiveness of balanced fluids and NS in pediatric sepsis.  
 
Of note, in our recent survey  (data unpublished) , 95% of PECARN investigators agreed that 
the existing adult and pediatric data are insufficient to reach consensus on the best 
crystalloid fluid  to use for resuscitation in pediatric septic shock . 
   [ADDRESS_776310] storage units of NS and LR will be used, including 250, 500, and 
1,000 mL units.  At the discretion of the care team, dextrose may be added to either NS or 
LR for resuscitation (uncommon) or maintenance (common) fluid therapy.  Co mmonly used 
dextrose preparations for pediatric septic shock include NS or LR with 5% or 10% dextrose 
which are also available in standard volumes of 250, 500, and 1,000 mL units.  Potassium or 
other electrolytes may be added to either NS or LR as clinical ly indicated.  
Volume for fluid resuscitation is typi[INVESTIGATOR_897] 10 -20 mL/kg per dose administered over 5 -20 
minutes via the intravenous or intraosseous route, though children with sepsis often receive 
>100 -200 mL/kg total crystalloid volume resuscitation within 24-48 hours.  Volume for 
maintenance fluids is typi[INVESTIGATOR_589387], assessment of intravascular 
volume status, and need for a specific glucose infusion rate.  However, for this study, only 
the type of base fluid (i.e., NS or LR) will be determined by [CONTACT_18113], while the actual 
volume administered (per bolus dose, per hour, and in total), duration of administration, and 
need for electrolyte additives (i.e., dextrose, potassium, others) will be at the complete 
discretion of the treati ng care team . 
The costs for NS and LR are equivalent, with both fluids at approximately $ 1-2.[ADDRESS_776311] approved for medical use by [CONTACT_34033] 
1971.  Both NS and LR are listed for use in pediatrics based on “clinical practice” and 
reference in the “medical literature”.  In the pediatric ED population, however, NS is 
overwhelmingly the more common fluid used for resuscitation of pediatric septic shock.15  
Therefore, we will consider NS to be the control fluid (since  >98% of patients not enrolled 
in this study would initially receive NS) and LR, the less commonly utilized fluid, the 
intervention fluid in this study .  Specific cautions for use of LR in the pediatric and critically 
ill population are shown in Table 2:  
Table 2:  FDA Contraindications and Warnings to LR Administration to the Pediatric 
and Critically Ill Population  
Concern  Type of Caution  Relevance to Pr opose d Study  
Pediatric Population :  
LR and ceftriaxone must not 
be simultaneously Contraindication  Not relevant, inclusion criteria are  age 
>6 months to <18  years (see page 11, 
section 3.4.1)  
   6 
administered (age ≤ 28 days)  
LR and ceftriaxone must not 
be simultaneously 
administered through the 
same infusion line (age >28 
days)  Contraindication  If both LR and ceftriaxone prescribed, 
usual, routine clinical practice  will be 
followed (see page 10, section 3.1.2)  
Lactate -containing solutions 
should be admi nistrated with 
caution to infan ts <6 months  Warning  Not relevant, inclusion criteria are age 
>6 months to <18  years (see page 11, 
section 3.4.1)  
Critically Ill Population :  
LR should not be 
simultaneously administered 
with citrate anticoagulated 
blood throu gh same 
administration set  Warning  If both LR and blood products are 
administered, usual, routine clinical 
practice  will be followed (see page 10, 
section 3.1.2)  
LR infusion must be stopped 
if suspected hypersensitivity 
develop  Warning  Usual, routine clin ical practice  will be 
followed (see page 10, section 3.1.2)  
Depending on volume and rate 
of infusion, infusion of LR can 
cause fluid overload and/or 
electrolyte abnormalities  Warning  Not relevant, volume and rate of 
infusion of both LR (and NS) are at the  
discretion of the clinical team and both 
fluid and electrolytes will be monitored 
as indicated as part of usual, routine 
clinical practice  (see page 10 -11, 
section 3.2.1)  
Cautious administration of LR 
to patients with hyperkalemia or 
cardiac disease  Warn ing  Eligibility criteria require treating 
clinician to determine it  is safe to 
administer both NS and LR (see page 
11, section 3.4.1) , with known 
hyperkalemia a specified exclusion 
criteria. In addition,  study fluid may be 
stopped at clinician’s discretio n if new 
data changes this determination during 
intervention phase (page 11, section 
3.1.2)  
Cautious administration of LR 
to patients with metabolic 
alkalosis  Warning  Not relevant, metabolic alkalosis rare 
during resuscitation in septic shock and 
study fl uid may be stopped at clinician’s 
discretion (page 11, section 3.1.2)  
Cautious administration of LR 
to patients with inability to 
metabolize lactate (e.g., 
fulminant hepatic failure)  Precaution  Although fulminant hepatic failure or 
complete inability to m etabolize lactate 
is rare in septic shock , eligibility criteria 
require treating clinician to determine it  
is safe to administer both NS and LR 
with known fulminant hepatic failure a 
specified exclusion criteria (see page 
11, section 3.4.1) . In addition, study 
   7 
fluid may be stopped at clinician’s 
discretion if new data changes this 
determination during intervention phase 
(page 11, section 3.1.2)  
Cautious administration of LR 
to patients with hypercalcemia  Precaution  Although  severe hypercalcemia is rare 
in pediatric septic shock , eligibility  
criteria require treating clinician to 
determine it  is safe to administer both 
NS and LR (see page 11, section 3.4.1) 
with known hypercalcemia a specified 
exclusion criteria. In addition, study 
fluid may be stopped at cl inician’s 
discretion if new data changes this 
determination during intervention phase 
(page 11, section 3.1.2)  
 
1.[ADDRESS_776312] attempted during the cholera 
outbreak of the 1830 ’s.  In a letter to the Lancet  published on June 2, 1832, Thomas Latta 
noted  with intravenous saline “improvement in the pulse and countenance is almost 
simultaneous, the cadaverous expression gradually gives place to appearances of returning 
animation, th e livid hue disappears, the warmth of the body returns. ”[ADDRESS_776313] reference to a solution similar to 
that of NS in the 1880’s.  Hartog Joakob Hamburger recognized that erythrocytes did not 
lyse when placed in NS and concluded that “the blood of man was isotonic with a NaCl 
solution of 0.9%”.43  Although these observations conceivably led to the “normal” moniker 
for 0.9% NS (nobody knows for sure), human plasma is actually closer to 0. 6% NaCl.  
Subsequent events leading to the widespread adoption of NS into clinical practice remain 
unclear.  LR was also born in the 1880’s when Sydney Ringer added calcium and potassium 
to saline after observing that inorganic constituents of pi[INVESTIGATOR_589388] b etter preserved frog heart 
muscle ex vivo  than just salt dissolved in distilled water.44  In 1932, the pediatrician Alexis 
Hartmann modified Ringer’s original formula in order to reduce the acidosis observed in 
infants  with diarrhea.43 
Although commonly used, an increasing body of literature now links the high chloride 
content and low SID of NS to acute kidney injury (AKI), acidemia, hyperkalemia, vascular 
perm eability, inflammation, coagulopathy, fluid overload, and death.25  In particular, when 
infused in large volumes —as is common in septic shock —NS induce s a hyperchloremic 
metabolic acidosis due to the dilution of plasma bicarbonate within a constant  carbon 
dioxide  environment in the absence of an alternative buffer.45  In blood with normal protein 
levels, the SID (abbreviated Na + K – Cl) is approximately +40 mEq/L.  Infusion of NS with 
a SID of 0 (154 Na + 0 K – 154 Cl) produces an acidemia.[ADDRESS_776314] identical storage and dosing volumes, and  are of proven clinical benefit , 
crystalloids fluids p rovide the ideal scenario for a large pragm atic comparative effectiveness 
trial.  The proposed pi[INVESTIGATOR_589389] a larger trial that will definitively determine the comparative effectiveness of 
NS versus LR in pediatric septic shock . 
 
Enrollment of patients as close to the initiation of fluid resuscitation is critical , and the lack 
of early enrollment has been a major criticism of previous fluid resuscitation trials in adult 
studies .22,23  In the [LOCATION_002], the majority of children begin fluid resuscitation in the 
emergency department in which the therapeutic goal is generally to achieve hemodynamic 
stability prior to transfer to an inpatient setting, including the intensive care unit.  
Consequently, fluid resuscitation with volumes up to (and exceeding) 80 mL/kg commonly 
occur in the pediatric ED.  Delaying e nrollment of patients until after admission to an 
intensive care unit, thus, risks substantial volume of pre -study fluid resuscitatio n that may 
dilute the main effect of a specified fluid intervention.  Such contamination with pre -study 
fluid resuscitation has been a primary criticism of previous sepsis studies focusing on adults 
admitted to an ICU, in which receipt of a mean fluid volu me of [ADDRESS_776315] of NS versus LR fluid.   
 
1.6 Compliance Statement  
This study will be conducted in full accordance with all applicable Children’s Hospi[INVESTIGATOR_589390] a ll applicable Federal and state laws and 
regulations including 45 CFR 46, 21 CFR Parts 50, 54, 56, 312,  and 314. .  We will also 
follow the Good Clinical Practice: Consolidated Guideline approved by [CONTACT_189900]  (ICH ) except for a limited  scope and timeframe for 
monitoring clinical adverse events (AEs) given the comparative effectiveness nature of the 
proposed study involving two interventions with routine clinical use in pediatric sepsis and 
well-documented efficacy and sa fety profiles  of both NS and LR . 
The investigators will perform the study in accordance with this protocol, will obtain 
consent when possible , and will report unanticipated problems involving risks to subjects or 
others  in accordance with The Children’s Ho spi[INVESTIGATOR_175353]. Collection, recording, and reporting of data will be 
   [ADDRESS_776316] IVES  
The purpose  of the proposed pi[INVESTIGATOR_589391] a large, 
pragmatic, randomized, open -label trial comparing the clinical effectiveness and safety of 
fluid resuscitation with NS versus LR for pediatric septic shock.  
2.1 Primary Objective (or Aim)  
The primary objective of this study is to determine compliance with study fluid 
administration, throughout the intervention phase, within each randomized arm using a 
pragmatic study design.   
Specifically, we will determine if the proposed study design is feasible to provide a 
clinically important difference in crystalloid fluid type  between the two study arms by 
[CONTACT_589425] 0.9% saline for 
pediatric patients with susp ected septic shock randomized to fluid resuscitation with either 
saline or lactated Ringer’s.  
2.2 Secondary Objectives (or Aim)  
The secondary objectives are to:  
 Estimate  the proportion of eligible pediatric patients with suspected septic shock who 
may be  enrol led into a large randomized pragmatic trial of fluid resuscitation with 
saline versus lactated Ringer’s.  
 Demonstrate feasibility  of patient enrollment into a pragmatic fluid resuscitation trial 
using Exception from Informed Consent (EFIC).  
  
   11 
3 INVESTIGATIONA L PLAN  
3.1 General Schema of Study Design  
The overall design for this pi[INVESTIGATOR_9962] a randomized, open -label pragmatic clinical trial of 
two different crystalloid fluids to resuscitate pediatric septic shock.  The two arms include 
0.9% “normal” saline (NS; co ntrol arm) and lactated Ringer’s (LR, intervention arm).  See 
Figure [ADDRESS_776317]  20 mL/kg 
intravenous  (IV)/intraosseous (IO) crystalloid fluid for clinical concern for septic shock.   To 
ensure rapid and appropriate eligibility and enrollment, ED staff (including ED attendings 
and fellows) will be included as study co -investigators and  be trained regarding study 
enrollment criteria and procedures.  
When time permits, p arental/guardian permission (informed consent) will be obtained prior 
to any study rel ated procedures being performed .  However, under most circumstances, the 
life-threaten ing nature of septic shock and the narrow therapeutic window for fluid 
resuscitation (on the order of minutes after presentation and shock recognition) will preclude 
sufficient time for an appropriate discussion of the study to properly seek informed conse nt 
and assent.  In these cases, enrollment will proceed under the conditions of “exceptio n from 
informed consent” (EFIC) with notification of the subject’s legally authorized representative 
(LAR) as described in Section 9.6.3.  
3.1.2 Intervention  Phase  
The inter vention to be tested is fluid resuscitation with LR compared to the “usual practice” 
control fluid of NS.   Other than prescribing which crystalloid fluid to use, the intervention 
will be purposely implemented without intense efforts to standardize timing a nd volume of 
fluid resuscitation or other components of clinical care.  
 
The proposed interventional plan is that, prior to receipt of >40  mL/kg of crystalloid bolus  
fluid , eligible patients will be randomized to receive either NS or LR for all remaining fl uid 
administration (bolus and maintenance) for  up to 48 hours.  T he study period will end at 
11:59pm on the calendar day following randomization such that all patients receive at least 
[ADDRESS_776318] fluid 
resuscitation is completed for septic shock.27 This time  point for terminating the intervention 
phase was selected because it provided a pragmatic endpoint that can be used by [CONTACT_589426].  Selective fluid 
administration has been previously shown to result in widely different amounts of saline 
use,47 though application of these findings in adults using a different allocation strategy to  
the one proposed for our study is not clear.  Study fluids will not be blinded due to costs and 
interventions that are not in keepi[INVESTIGATOR_18499] a simple, pragmatic trial and based on results from 
the previously published SPLIT fluid trial in which two -thirds o f clinicians correctly 
   12 
identified the randomized crystalloid patients received (despi[INVESTIGATOR_589392]) as electrolyte 
differences following NS or LR provide clea r indication of fluid selection.35  The volume 
and need fo r additional fluid, as well as all other aspects of care, will be at the discretion of 
the treating team  which will be educated to follow the CHOP ED and/or PI[INVESTIGATOR_589393] (see 
Appendix 5) .  All other care will be at the discretion of the clinical team.  As study fluids 
will not be blinded, patient -level randomization will minimize selection bias due to 
awareness of group assignment.  Study fluids can be stopped for clini cian concerns noted 
during routine care (e.g., hyponatremia, hyperkalemia, hypercalcemia, cerebral edema).  
Adherence to the study intervention will be monitored through random chart audits of both 
eligible subject enrollment and the volume of study arm cr ossover .  Study arm cross -over is 
defined as a subject randomized to NS who subsequently receives LR during the 
intervention period or a subject randomized to NS who subsequently receives NS during the 
intervention period.  
 
NOTE:  Because calcium -containin g solutions, including LR, can precipi[INVESTIGATOR_589394], teams will be 
educated to follow usual, routine clinical practice  for administration of LR with ceftriaxone.  
This includes use of either different infusion lines or, if the same infusion in used for 
sequential administration, then the line must be thoroughly flushed between infusions with a 
compatible fluid as per usual, routine clinical practice .  These practices are consistent with  
usual, routine care  that would otherwise be performed for patients prescribed LR outside of 
this study.   An example of existing safety mechanisms within usual, routine clinical practice 
is that the following warning is issued within the electronic order e ntry system to advise 
caution when ceftriaxone is prescribed and administered:  
 
“Ceftriaxone and calcium -containing solutions may be administered sequentially of one 
another for use in patients greater than28 days  if infusion lines are thoroughly flushed 
(with a compatible fluid) between infusions.”  
In addition, clinical staff will also be targeted for education about safe administration of LR 
with other medications, such as ceftriaxone, prior to and throughout the study.  
 
NOTE:  Because LR should not be ad ministered simultaneously with citrate anticoagulated 
blood through the same administration set, teams will be educated to follow usual, routine 
clinical practice  for administration of LR with blood products.   Clinical staff  will be targeted 
for education about safe administration of LR with blood products prior to and throughout 
the study.  
 
NOTE:  Both NS and LR pose risk of a hypersensitivity reaction during IV/IO infusion.  
Teams will be educated to following usual, routine clinical practice  for disconti nuation of 
administration of study fluid if signs and/or symptoms of hypersensitivity reaction develops.  
 
3.1.3 Follow -up Phase  
After 11:[ADDRESS_776319] . 
3.2 Allocation to Treatme nt Groups and Blinding  
Randomization will be performed using 1:1 permuted blocks .  Randomization sequence will 
be generated prior to the start of the study and will be filed using a series of numbered, 
opaque envelopes.  Envelopes with study arm assignment  will be stored in close proximity 
to crystalloid fluids in the CHOP ED.  Treatment allocation will be revealed to the clinical 
care team after eligibility for enrollment has been determined to be appropriate by [CONTACT_7939] a 
member of the care team to open the  next sequentially numbered envelope.  The number of 
the envelope and study arm assignment will be recorded in a log after opening the envelope.  
The clinical team will then be directed to use the  assigned study fluid for all subsequent 
crystalloid fluid a dministration within  the remainder of the study window.   Compliance with 
study fluid administration will be the primary feasibility assessment in this study (Aim 1).    
Fluid administration will be open -label and neither the subject nor the care team will b e 
blinded to the allocated treatment assignment.  Blinding study fluid is not pragmatic and 
unlikely to even be possible. In the SPLIT fluid trial, two -thirds of clinicians correctly 
identified the randomized crystalloid patients received as electrolyte di fferences following 
NS or LR provide clear indication of fluid selection.[ADDRESS_776320] will be up to 90 days, with up to 1 day  for screening, up to 2 
days for Phase 1  (Intervention Phase) , and up to  89 subse quent  days (or until hospi[INVESTIGATOR_7954], whichever comes first)  for follow -up. 
3.3.2 Total Number of Study Sites/Total Number of Subjects Projected  
The study wil l be conducted at one  investigative site  in the [LOCATION_002]  (the Children’s 
Hospi[INVESTIGATOR_589395] a). The University of Utah will act as the Data Coordinating Center 
(DCC) for this study, but they will not be engaged in human subjects research.  Their role is 
limited to the receipt of a limited dataset from the CHOP investigators.  
Recruitment will stop  when [ADDRESS_776321], heterogeneous cohort of pediatr ic patients 
with suspected septic shock who are easily recognizable within routine clinical practice and 
   14 
are representative of the broader population of pediatric patients treated for suspected septic 
shock.  
3.4.1 Inclusion Criteria  
1) Males or females age >6 month s to <18 years  
2) Clinician concern for septic shock, operationalized as:  
a) a “positive” ED sepsis alert confirmed at the physician led “sepsis huddle” OR  
b) a physician diagnosis of suspected septic shock requiring parenteral antibiotics and 
fluid resuscitation a s per the ED sepsis management pathway  
NOTE:  Condition 2a above is met by:  
A. Tachycardia or hypotension for age AND  
B. Fever (home or ED >38 °F), hypothermia, or other signs/symptoms of infection 
AND  
 
At least one of C, D, or E  
 
C. Flash (< 1 second) or delayed (>3 seconds) capi[INVESTIGATOR_39093]  
D. Altered mental status  
E. Existing high -risk condition, including:  
i. <56 days -old 
ii. Asplenia  
iii. Bone marrow or solid organ transplant  
iv. Central venous catheter  
v. Malignancy  
vi. Significant neurological dysfunction or technological dependence at 
baseline  
vii. Other immunodeficiency or immunocompromised  
 
As per the existing CHOP ED Sepsis Alert, the presence of A and B and either C, D, or 
E will be determined by [CONTACT_589427] (and then continuously by [CONTACT_589428]).  If these criteria are met, then a “sepsis huddle” will be 
called with immediate physician bedside patient evaluation for possible septic shock.  
Patients who are considered to have suspected septic shock will be treated on the CHOP 
ED sepsis mana gement protocol (Appendix 5) and will be considered for study 
eligibility  
NOTE:  Condition 2b above is met by [CONTACT_589429] a “sepsis 
huddle” but is diagnosed by [CONTACT_589430].  
Combining both the nurse -driven electronic sepsis alert with physician judgement to identify 
suspected septic shock in the CHOP emergency department, we have documented a 99.4% 
sensitivity and 99.1% specificit y to identify patients who met international consensus 
criteria for severe sepsis/septic shock while only 5.5% of ED patients who developed severe 
   15 
sepsis/septic within 24 hours of ED presentation were missed.48  However, because the 
positive predictive value of this combined approach was 25.4%, we have required the 
additional inclusion criterion of administration of at least 20 mL/kg IV/IO fluid resuscitation 
with additional fluid deemed likely to be necessary to tr eat poor perfusion, defined as either 
hypotension or abnormal (either “flash” or > 3 second) capi[INVESTIGATOR_39093] (as determined by 
[CONTACT_30223]’s judgment).  
 
3) Administration of at least 20 mL/kg IV/IO fluid resuscitation  
4) Receipt of ≤ 40 mL/kg IV/IO crystalloid fluid prior to randomization  
5) Additional fluid deemed likely to be necessary to treat poor perfusion, defin ed as either 
hypotension  or abnormal (either “flash” or >2 second) capi[INVESTIGATOR_39093] (as determined by 
[CONTACT_30223] ’s judgment)10 
NOTE:  Due to the pragmatic nature of this study that is designed to reflect usual clinical 
practice, we will not define specific thresholds for either hypotension or abnormal capi[INVESTIGATOR_589396]’s discretion to determine hypotension and 
abnormal capi[INVESTIGATOR_39093].  
6) Parental/guardia n permission (informed consent) if time permits; otherwise, EFIC 
criteria met  
NOTE:  For patients who may be transferred to the CHOP E D from an outside facility, 
many will have started fluid resuscitation prior to arrival in the CHOP ED.  If volume of 
crystalloid fluid adm inistration cannot be easily determined such that receipt of ≤40 mL/kg 
IV/IO crystalloid volume cannot be easily veri fied, these patients will be operationalized as 
not meeting the ≤40 mL/kg inclusion criterion.  
NOTE:  Patients who are randomized to a study arm at ≤40 mL/kg crystalloid fluid 
resuscitation but for whom study fluid is not initiated until after >40 mL/kg  will still be 
included and should commence with administration of study fluid for the duration of the 
remaining intervention phase.  
3.4.2 Exclusion Criteria  
Reflecting the pragmatic design of the proposed study , exclusion criteria are purposely 
limited  to ensure maximal external validity .  FDA listed “contraindications” to LR are 
reflected as absolute exclusions (e.g., age < 6 months), while FDA listed “warnings”  and 
“precautions”  to LR administration are incorporated into the below listed exclusion criteria 
(see Table 2 in Section 1.4 for summary of FDA recommendations for use of LR in the 
pediatric and critically ill population).  In addition, exclusion criteria are operationalized to 
reflect  the common clinical practice (and guideline recommendations) to begin 
administration of either NS or LR to resuscitate septic shock without delays imposed by 
[CONTACT_589431].    
   16 
1) Clinician judgement that patient’s condition deems it  unsafe to administer either NS or 
LR (since patients will be equally lik ely to receive NS or LR at time of study 
enrollment) , including  (but not limited to) : 
a) Clinical suspi[INVESTIGATOR_589397]  
b) Known hyperkalemia, defined as non -hemo lyzed whole blood or plasma /serum  
potassium > 6  mEq /L, based on data available at or before patient meets criteria for 
study enrollment  
c) Known hypercalcemia, defined as plasma /serum  total calcium >12 mg/dL or whole 
blood ionized calcium > 1.3 5 mmol/L , based  on data available at or before patient 
meets criteria for study enrollment  
d) Known acute fulminant hepatic failure, defined as plasma/serum ALT >10,000 U/L  
or total bilirubin >12.0 mg/dL , based on data available at or before patient meets 
criteria for study  enrollment  
e) Known history of severe hepatic impairment, defined as diagnosis of cirrhosis, “liver 
failure”, or activ e listing for liver transplant  
f)   Known history of severe renal impairment, defined as current dependency on 
peritoneal dialysis or hemodialy sis 
g) Known metabolic disorder, inborn error of metabolism , or primary mineralcorticoid  
deficiency (e.g., mitochondrial disorder, urea cycle disorder, amino acidemia, fatty 
acid oxidation disorder, glycogen storage disorder, congenital adrenal hypoplasia, 
Addison’s disease ) as reported by [CONTACT_1130], LAR or accompanying caregiver, or as 
listed in the medical record  
NOTE:  Due to the short therapeutic time window available for fluid resuscitation —and 
therefore study enrollment (see Section 3.1.1. )—in pediatric se ptic shock, it is not feasible to 
wait for diagnostic tests to identify medical conditions.  Therefore, exclusion will be based 
on medical conditions that are known (or, in the case of impending brain herniation, 
suspected) at or before the time a patient otherwise meets criteria for study enrollment.   If 
such data are not available and the treating clinician does not otherwise, in his/her best 
judgement, deem it unsafe to administer either NS or LR, then the patient will be eligible for 
study enrollment if  they meet all other inclusion and exclusion criteria.  Given the dynamic 
nature of sepsis, should an enrolled subject be noted to have a condition for which further 
administration of either NS or LR is deemed to be unsafe, the subject will be withdrawn 
from further study fluid administration. Because potassium, calcium, and liver function tests 
are already measured in all patients with suspected septic shock as part of routine care, there 
is no specific mandate to measure these values for the sole purposes  of this study.  
2) Known pregnancy determined by [CONTACT_589432]/or 
LAR  (or other accompanying acquaintance)  
NOTE:  The exclusion of pregnant women is indicated  under the provisions for “exception 
from informed consent” rathe r than a specific need to exclude pregnancy women from the 
interventions to be test in this study.  Given the  absence of data or plausible  adverse 
biological effect for either NS or LR in pregnancy  (see FDA inserts for NS and LR in 
Appendix 1 and Appendix 2, respectively) , the recommended use of crystalloid fluid for 
resuscitation of pregnant women with septic shock,12 and the absence of data supporting a 
   17 
relative difference in efficacy or safety for use of NS versu s LR on the developi[INVESTIGATOR_589398] ,49 there is no specific need to exclude pregnant women from the 
interventions to be tested in this study  beyond the requirements for enrollment under 
“exception from informed consent” . In addition, since 2012, none  of the 1,[ADDRESS_776322].  Therefore, because 
waiting for biochemical testi ng for pregnancy (e.g., urine β -HCG) would either cause most 
post-pubertal female patients become in eligible for enrollment (due to receipt of >40 mL/kg 
of fluid) or delay fluid resuscitation (putting potential subjects at risk of harm)  and given the 
extre mely low risk for diagnosing pregnancy in this patient population and given the safe 
use of both NS and LR in pregnancy , there will not be a  requirement to delay study 
enrollment while awaiting results of a pregnancy test.   Any subject enrolled in the stud y who 
is subsequently determined to be pregnant as part of routine clinical care, which at CHOP 
includes testing for pregnancy in all female patients of child -bearing age, will be 
immediately withdrawn from this study.   
3) Known prisoner as determined by [CONTACT_589433]/or LAR 
(or other accompanying acquaintance)  
4) Known allergy to either normal saline or lactated Ringer’s as determined by [CONTACT_589434]/or LAR (or other accompanying acquaintance)  
or as indicated in the medical record  
5) Indication of prior declined consent to participate based on presence of a “PRoMPT 
BOLUS Opt -Out” bracelet  with appropriate messaging embossed into the bracelet  (see 
IRB study 17 -013950 ) or the presence of the patient ’s name [CONTACT_589469] -out list that will 
be kept up -to-date and checked prior to randomization.  
Concurrent participation in another interventional trial will not be considered an exclusion 
criteria because such co -enrollment is not expected to impact the feasi bility aims and 
outcomes for this study.  
Subjects that do not meet all of the enrollment criteria may not be enrolled. Any violations 
of these criteria must be reported in accordance with IRB Policies and Procedures.  
  
   18 
4 STUDY PROCEDURES  
4.1 Screening Visit  
Patients will be screened at arrival to the ED (i.e., at ED triage) and continuously throughout 
the ED course for presence of eligibility criteria.  Referrals for potential subject enrollment 
will be made by [CONTACT_589435].  Although all members of the ED 
care team may participate in subject referral , a member of the study team will review and 
concur with the treatment team’s eligibility asse ssment prior to enrollment of the subject.    
To ensure rapid and appropriate eligibility and enrollment, ED staff (including ED 
attendings and fellows) will be included as study co -investigators and be trained regarding 
study enrollment criteria and proce dures   Once patients are determined to be eligible, the 
following study procedures will occur:  
 Informed Consent  (if time permits) or determination of EFIC  
 Randomization  
In addition, review of the daily ED triage logs and use of the ED sepsis pathway order  set 
will be performed by [CONTACT_589436].  The reason for non -enrollment for all eligi ble patients will be determined  by 
[CONTACT_589437]/or relevant members of the  clinical care 
team.  
4.2 Intervention  Phase  
The intervention phase will start immediately following the patient’s first 20 mL/kg and 
randomization has been determined, and will end at 11:59 pm on the calendar day following 
randomization.  During this period, the follow study procedures will occur:  
 Dispense study fluid  
 Monitor study fluid adherence  
 If enrollment after EFIC, review inclusion/exclusion criteria  
 If enrollment after EFIC, inform subject and LAR of study enrollment (as soon as 
feasibly possible)  
 Medical record review  
 Adverse event reporting  
4.3 Follow -up Phase  
The follow -up phase will start after 11:[ADDRESS_776323].  During this period, the following study procedures will occur:  
   19 
 Open -label fluid treatment  
 If enrollment after EFIC and not accomplished during intervention phase, inform 
subject and LAR of study enrollment (as soon as possible)  
 Medical record review  
 Adverse event repo rting  
 Outcome assessment  
4.4 Concomitant Medication  
All prior and concom itant use of antibiotics, acyclovir, corticosteroids, bicarbonate, parental 
calcium, blood products, crystalloid and colloid fluids (including hypertonic saline), 
mannitol, intravenous imm unoglobulin, diuretics, non -steroidal anti -inflammatory 
medications (NSAIDS), unfractionated or low -molecular weight heparin, vasoactive 
infusions (i.e., dopamine, dobutamine, epi[INVESTIGATOR_238], norepi[INVESTIGATOR_238], phenylephrine, 
milrinone, vasopressin) within one d ay prior to the screening visit and through the end of the 
study will be recorded. The dates of administration, dosage, and reason for use will be 
included.  
4.5 Rescue Medication Administration  
Open -label use of hypertonic saline, mannitol, unfractionated or low-molecular weight 
heparin, systemic or local tissue plasminogen activator (tPA), or other “blood thinner”, 
parenteral calcium, and parenteral bicarbonate will be recorded, including dates of 
administration, dosage, and reason for use.  
4.[ADDRESS_776324] Completion /Withdrawal  
Subjects may withdraw from the study at any time without prejudice to their care , including 
following notification of study enrollment under EFIC.  Subjects  may also be discontinued 
from the study at the discretion of the Investigator (at any p oint) for lack of  adherence to 
study treatment or at the discretion of the attending physician of record (during the 
intervention phase only) if his/her clinical judgment deems it no longer safe to continue to 
administer either NS or LR .  The Investigator may also withdraw subjects to protect the 
subject for reasons of safety or for administrative reasons.  It will be documented whether or 
not each subject completes the clinical study. If the Investigator becomes aware of any 
serious, related adverse events  after the subject completes or withdraws from the study, they 
will be recorded in the source documents and on the CRF.  
4.6.[ADDRESS_776325] all procedures enumerated for the follow -
up phase in Section 4.3 performed at the early termination point  (rather than at hospi[INVESTIGATOR_589399] 90).   
In addition, subjects randomized to LR in this unblinded study for whom routine, clinician -
directed physical and/or laboratory assessment reveals the following c riteria within the up -
   20 
to-48 hour time window of the intervention phase will not be required to receive additional  
study fluid  as part of this protocol  and will be transitioned to an appropriate fluid as 
determined by [CONTACT_589438].  Recognizing that hepatic and 
renal injury are a) common in septic shock, b) often improved by [CONTACT_589439], and c) 
vary along a spectrum of mild dysfunction (common) to severe failure (uncommon), 
stoppi[INVESTIGATOR_589400] (e.g., potassium administration despi[INVESTIGATOR_589401]).  
 Hyperkalemia defined as blood  potassium >6 mEq/L confirmed on immediate repeat 
testing  
 Hypercalcemia defined as blood total calcium >12 mg/dL or ionized calcium >0.35 
mmol/L confirmed on immediate repeat testing  
 Severe hepatic impairment  defined as rise in blood ALT to >10,000 U/L or total 
bilirubin >12.0 mg/dL  
 Severe renal impairment defined as initiation of renal replacement therapy 
(continuous or intermittent hemodialysis or peritoneal dialysis) or urine output <0.5 
ml/kg/hr for 16 hou rs 
 
NOTE:  Hepatic impairment was defined as a fulminant rise in ALT or total bilirubin 
because other markers of liver function are not commonly recommended for use in pediatric 
septic shock.  For example, an acute elevation in INR is more commonly indicat ive of 
hematologic dysfunction than hepatic impairment in pediatric septic shock.50 
 
NOTE:  Urine output <0.5 ml/kg/hr for 16 hours indicates renal injury (“I”) in the pRIFLE 
scoring system and stage II kidney injury in the KDIGO  scoring system.51  Creatinine and 
creatinine clearance will not be used as stoppi[INVESTIGATOR_589402] a poor proxy for a patient’s handling of potassium in that most acute kidney injury in 
sepsis is caused by [CONTACT_240074], which promotes electrolyte wasting despi[INVESTIGATOR_040] a rise 
in blood creatinine.  As an example, in a prior randomized trial of NS versus LR following 
kidney transplant (as a model of  severe acute kidney injury), 19 % of patients in the NS 
developed hyperkalemia >6 mEq/L compared to 0% in the LR group.[ADDRESS_776326] wide variability in illness severity and clinical course, including large 
differences in the amount and timing of fluid administration, pre -specifying which 
laboratory values to obta in and when to obtain them could result in additional unnecessary 
phlebotomy and/or access of indwelling lines both of which would impose additional harm 
(e.g., pain) and risk (e.g., central -line associated bloodstream infection risk increases with 
additio nal line accesses) that may not have been experienced outside of the study.  
Therefore, rather than pre -specifying in the study protocol the laboratory values to obtain 
   21 
and the time points or timeframe at which to obtain them, the study protocol will utili ze the 
institution’s existing laboratory recommendations within the clinical sepsis pathway, which 
includes potassium and total calcium at least every 12 hours, ionized calcium every 2 hours  
(as part of blood gas analysis) , and ALT and bilirubin every 24 h ours for patients with active 
septic shock admitted to the pediatric intensive care unit  (with more frequent laboratory 
assessments in the subset of patients with more severe illness undergoing ongoing fluid [and 
other] resuscitation) .  At CHOP, t here are no hospi[INVESTIGATOR_589403].  It is anticipated that ongoing fluid resuscitation outside of the 
ED setting will be almost exclusively limited to patients who require admission to the PI[INVESTIGATOR_6890], 
such that the existing clinical sepsis pathway will prompt clinicians to ascertain laboratory 
values appropriately in those patients at risk for fluid -related abnormalities for whom stu dy 
fluids will no longer be recommended.  The timeframes included within the clinical sepsis 
pathway provide adequate windows to re -assess safety of ongoing study fluid administration 
because these potential adverse laboratory effects are related to cumulat ive fluid 
administration rather than any one particular fluid bolus.  
 
For subjects randomized to either NS or LR in whom routine, clinician -directed physical 
and/or laboratory assessment reveals clinical concern for hypersensitivity to the study fluid 
to which they were randomized, will not be required to receive additional study fluid as part 
of this protocol within the up -to-48 hour time window of the intervention phase . 
 
Any subjects who meet the above “stoppi[INVESTIGATOR_3418]” will remain in the study for dat a 
collection and outcome assessment.  Clinician -prescribed fluid administered within the 
intervention phase will continue to be recorded, including any potential continued use of LR 
and/or alternative fluid.  
 
 
   [ADDRESS_776327] Review  
The following  variables will be abstracted from the medical chart (paper or electronic).  
 Name  
 Medical record number  
 CSN number  
 Date/time ED arrival and triage  
 Date/time of transfer/discharge  from the ED  
 Date/time of hospi[INVESTIGATOR_063]  
 Date/time of PI[INVESTIGATOR_7035]  
 Date of birth  
 Race  
 Ethnicity  
 Comorbid medical/surgical conditions  
 Pre-hospi[INVESTIGATOR_219305]  
 Date, time, and volume of all study fluid administration  
 Date, time, and volume of all non-study parenteral fluid administration, including all 
crystalloids, colloids, blood productions, medications, continuous infusions, and 
flushes  
 Total d aily recorded volume administered (all “in’s”) and excreted/removed (all 
“out’s”)  
 Date/time of medications/ pharmaceuticals administrated during ED and 
hospi[INVESTIGATOR_059]  
 Laboratory tests  (including date/time and results)  
 Microbiology tests  
 Radiological tests  
   23 
 Date/time of PI[INVESTIGATOR_173992]/discharge  
 Date/time of hospi[INVESTIGATOR_2345]  
 Vital status at hospi[INVESTIGATOR_2345], st udy withdrawal, or [ADDRESS_776328] step towards 
a larger, multicenter comparative effectiveness study which will determine the relative  
efficacy and safety of NS versus LR.  The relative benefit one fluid ove r the other was not 
been proven or even sufficiently tested in large prospective studies and there is, therefore, 
equipoise for the question of comparative effectiveness.   The goal of the comparative 
effectiveness study will be to determine if there are cl inically overt and significant benefits 
of either NS or LR, relative to each other.  We therefore will seek to measure clinically overt 
and significant efficacy and safety outcomes which would be identified as part of routine 
clinical practice rather than specifying biochemical laboratory tests that may identify values 
outside the range of normal but would not otherwise be considered “clinically overt and 
significant”.  For example, there is no compelling reason to shift clinical practice from 
predominant N S resuscitation to predominant LR resuscitation solely because of 
hyperchloremia if this biochemical abnormality does not translate into a “clinically over t and 
significant” patient outcome.  For these reasons, no laboratory testing will be required 
beyond  that which is performed as part of routine clinical practice.  However, as described 
in Section 6.3.4, for the purposes of this feasibility study, we will track laboratory testing 
performed as part of routine clinical practice in order to determine the fr equency that 
laboratory results are available for the specified safety outcome measures listed in Section 
5.4.  In addition, if the designated “stopp ing criteria” listed in Section 4.6.1 are identified 
during the course of routine, clinician -directed physi cal and/or laboratory assessment , no 
further study fluid will be recommended.  
5.1.3 Radiographic Evaluations  
No routine radiographic evaluations will be required as part of this study.  However, 
radiographic studies  that are performed during the course of routin e clinical care will be 
   24 
abstracted from the medical chart  as needed to determine site of infection, diagnosis of 
venothromboembolism, and diagnosis of cerebral edema/intracranial hypertension .  
5.2 Feasibility  Evaluations  
5.2.1 Aim 1  
The primary outcome for Aim 1 will be the proportion of total crystalloids administered as 
saline in each arm, and the secondary outcome will be the proportion of total crystalloids 
administered as non -study fluid (i.e., cross -over) in each arm . 
The primary outcome will be measured in ea ch subject by [CONTACT_589440] (in mL) 
of NS administered as fluid boluses or continuous IV/IO fluids (numerator)  by [CONTACT_589441] (in mL) of all crystalloids (NS, LR, and Plasma -lyte [with or without dextrose 
and/or other electrolyte additives ]) administered as fluid boluses or continuous IV/IO fluids 
during the intervention phase (denominator).  NS or LR (or other crystalloid) administered 
to “flush” a medication or check line patency , as a “carrier” fluid designed to maintain 
IV/IO patency or  assist delivery of another medication,  or used solely as a diluent for 
another medication will be excluded from both the numerator and denominator.  
The secondary outcome will be measured in each subject by [CONTACT_589440] (in 
mL) of non -study fl uid given as either NS (for patients randomized to the LR arm) or LR 
(for patients randomized to the NS arm), including pre -study enrollment crystalloid fluids 
(numerator) , by [CONTACT_589442] (in mL) of NS plus LR [with or without dextrose and/or 
other el ectrolyte additives]) administered as fluid boluses or continuous IV/IO fluids during 
the intervention phase (denominator).  NS or LR (or other crystalloid) administered to 
“flush” a medication or check line patency, as a “carrier” fluid designed to mainta in IV/IO 
patency or assist delivery of another medication, or used solely as a diluent for another 
medication will be excluded from both the numerator and denominator.  
5.2.2 Aim 2  
The outcome for Aim 2 will be the proportion of eligible patie nts treated in the C HOP ED  
who are enrolled, randomized, and treated with study fluid.  This outcome will be measured 
by [CONTACT_589443], 
randomized, and treated with study fluid (numerator) by [CONTACT_589444] (denominator)  over the entire enrollment period of the study . 
5.2.3 Aim 3  
The outcome s for Aim 3 will be the proportion of eligible patients who meet criteria for 
EFIC who are  not enrolled, randomized, and treated with  study fluid  or, if enrolled, 
withdraw prior to completion of the follow -up phase.  This outcome will be measured by 
[CONTACT_589445]/or withdraw prior 
to completion of the follow -up phase (numerato r) by [CONTACT_589446] (denominator)  over the entire enrollment period of the study . 
   25 
5.3 Efficacy  Evaluation  
This pi[INVESTIGATOR_589404].  However, the following efficacy 
outcomes planned  for use  in a subsequent large pragmatic trial will be measured:  
 All-cause hospi[INVESTIGATOR_34380]  (censored at 90 days following randomization), 
measured as vital status at hospi[INVESTIGATOR_2345]  
 Hospi[INVESTIGATOR_307] -free days, measured as the number of calendar days alive an d out of the 
hospi [INVESTIGATOR_589405] (day 0) and day 27 .  Patients who die prior to 
hospi[INVESTIGATOR_589406] “zero” hospi[INVESTIGATOR_307] -free days.  Because follow -up 
will not proceed after hospi[INVESTIGATOR_2345], patients who may have died after hosp ital 
discharg e but before day 27  will be recorded as having as many  hospi[INVESTIGATOR_307] -free days up 
to day 27  as if they had survived to day 27 . 
 New inpatient dialysis, measured as treatment (or intention to treat if subject does 
not tolerate treatment) with any ren al replacement therapy (including slow 
continuous ultrafiltration, continuous or intermittent hemodialysis, hemofiltration, or 
hemodiafiltration, or peritoneal dialysis) that was not a continuation of pre -hospi[INVESTIGATOR_589407].  
 Hospi[INVESTIGATOR_7577] , measured as the number of calendar days between ED arrival 
and ED or h ospi[INVESTIGATOR_2345] (whichever occurs later) . 
5.4 Safety Evaluation  
This pi[INVESTIGATOR_589408].  However, the following safet y 
outcomes planned for use  in a subse quent large pragmatic trial will be measured  if 
ascertained as part of routine clinical practice : 
 Hyperlactatemia, measured as at least one venous or arterial blood lactate 
measurement >4 mmol/L within four calendar days of randomization  
 Hyperkalemia, meas ured as at least one venous or arterial blood potassium 
measurement >6 mEq/L (without hemolysis) within four calendar days of 
randomization  
 Hypercalcemia, measured as at least one venous or arterial  blood  ionized calcium 
measurement of >1.3 5 mEq/L or total  calcium >12 mEq/L within four calendar days 
of randomization  
   26 
 Hypernatremia , measured as at least one venous, arterial, or capi[INVESTIGATOR_589409] >155 mEq/L within four calendar days of randomization  
 Hyponatremia, measured as at least one ve nous, arterial, or capi[INVESTIGATOR_589409] <128 mEq/L within four calendar days of randomization  
 Hyperchloremia, measured as at least one venous, arterial, or capi[INVESTIGATOR_589410] >110 mEq/L within four  calendar days of ran domization  
 Clotting of intravenous line in patients who received both ceftriaxone and LR, within 
four calendar days of randomization  
 Therapy for brain herniation, measured as treatment with hyperosmolar therapy 
(hypertonic saline and/or mannitol) for radio graphic and clinical determination of 
new impending or present brain herniation (but not including a presumptive clinical 
diagnosis of brain herniation that is disproven by [CONTACT_589447]) 
within four calendar days of randomization  
 Therapy  for thromboembolism, measured as radiographic or clinical determination 
of new venous or arterial thromboembolism requiring initiation of therapeutic 
anticoagulation for the purposes of treating thromboembolism , within seven  calendar 
days of randomization  
   27 
6 STATISTICAL CONSIDER ATIONS  
6.1 Primary Endpoint  
The primary endpoint will be the proportion of total crystalloids administered as saline in 
each arm during the intervention phase (Aim 1) . 
6.2 Secondary Endpoints  
Secondary endpoints will include the following:  
 The proportion of total crystalloids administered as non -study fluid (i.e., cross -over) in 
each arm  (Aim 1).  
 The proportion of eligible patients treated in the pediatric ED who are enrolled, 
randomized, and treated with study fluid (Aim 2).  
 The proportion of  eligible patients who meet criteria for EFIC who are enrolled, 
randomized, and treated with study fluid and do not withdraw prior to completion of the 
follow -up phase.  
 
6.[ADDRESS_776329] descriptive 
summaries (e.g. means and standard deviations for continuous variables such as age and 
percentages for categorical variables such as gender).  
6.3.2 Feasibility  Analysis  
The primary analysi s will be based on an intention -to-treat approach and will include all 
subjects randomized whether or not study fluid was administered .   
The primary endpoint will be defined as meeting feasibility criteria if either  of the following 
criteria are met:  
3) There is an absolute difference in the mean u se of NS between arms of at least  65% 
with a lower 95% CI border of >60%.  For example, feasibility criteria would be met 
if 90% of crystalloid fluid in the NS arm was NS compared to only 25% in the LR 
arm.  The proportion of NS use in each arm will be com pared using the chi -squared 
test with a 95% bootstrap confidence interval with bias correction (assuming skewed 
distribution of data) around the difference in the proportion of NS use in each arm.  
4) At least 85 % of subjects in the NS arm receive ≥90% of study  fluid as NS during the 
study window and at least 80% of subjects  in the LR arm receive ≥75% of study  
fluid as LR. 
The secondary endpoints will be defined as meeting feasibility criteria if:  
   28 
 The mean proport ion o f total crystalloids administered as non -study fluid (i.e., cross -
over) is ≤ 25% in each arm (for example, ≤25% of total crystalloid is administered as 
NS for patients randomized to the LR arm).  
 The proportion of eligible patients treated in the pedia tric ED who are enrolled, 
randomized, and treated with study fluid is >65%.  
 EFIC is approved by [CONTACT_589421]  
 The proportion of eligible patients who mee t criteria for EFIC who are not  enrolled 
or who are enrolled but withdraw prior to completion of the follow -up phase is 
≤10%.  
6.3.[ADDRESS_776330]’s medical record or other confidential records 
requiring the subject’s consent. Howev er, an investigator may review study data related to 
the subject collected prior to the subject’s withdrawal from the study, and may consult 
public records, such as those establishing survival status  
6.3.4 Safety Analysis  
Safety endpoints will be tracked between  groups as part of this pi[INVESTIGATOR_799], but no formal 
statistical comparisons will  be undertaken due to insufficient statistical power.   As part of 
our secondary feasibility analysis, however, we will determine the proportion of patients 
with complete data av ailable for each safety endpoint listed in Section 5.5 to ensure that it is 
indeed feasible to capture the safety outcome measures planned for a subsequent large 
multicenter trial.   Specifically, we will track laboratory testing performed as part of routin e 
clinical practice in order to determine the frequency that laboratory results are available for 
the specified safety outcome measures listed in Section 5.4.  It is notable that routine clinical 
practice for sepsis includes frequent (i.e., daily or more) measurement of blood lactate, 
sodium, potassium, chloride, and calcium.  
6.4 Sample Size and Power  
In a previous PECARN study called the FLUID trial  (data not yet published) , nearly 1400 
pediatric patients presenting to the ED with diabetic ketoacidosis (DKA) w ere randomized 
to different fluid volumes and different fluid types (normal saline vs. half -normal saline).  
   [ADDRESS_776331] like the  half-NS arm (i.e., the study 
intervention arm) and the NS arm will behave like the NS arm (i.e., the control arm) in the 
FLUID trial.  In the FLUID trial, the mean percentage of correct fluid given was 96% in the 
NS arm and 91% in the half -NS arm.  About 90% of subjects in the NS arm received at least 
85% NS, while about 89% of those in the half -NS arm received at least 75% half -NS.  
Through simulation, by [CONTACT_589448], with [ADDRESS_776332] 85% of subjects  in the NS arm and 80% in the LR arm will receive 
the “adequate” amount of correct study fluids (i.e., ≥90% of study fluid as NS in NS arm 
and ≥75% of study fluid as LR in the LR arm) is approximately 80% (study power for 
criterion #2 of the Aim 1 feasibil ity analysis described in Section 6.3.2).  
6.[ADDRESS_776333] 36 subjects (approximately 18 per group).  An imbalance of 
at least six deaths will provide statistical significance at the level of 0.05 betwe en the two 
groups.  Hospi[INVESTIGATOR_589411].  If the potential early stop rule is reached, the DCC will provide these data to 
the DSMB for an interim review and consideration to procee d versus terminate the study 
based on their review of the study data, cause of death, and/or other possible data deemed 
necessary by [CONTACT_4318].  
   30 
7 STUDY MEDICATION  
7.1 Description  
Existing hospi[INVESTIGATOR_589412].  
7.1.1 Packaging  
Both NS and LR will be supplied in their usual bags and/or syringes that are in current use 
as part of routine clinical practice.  
7.1.2 Labeling  
Only FDA -approved hospi[INVESTIGATOR_307] -issued fluids will be used for this study.  The current supply of 
fluids used at CHOP to be included in this study is NS manufactured by [CONTACT_589449].  Both NS and LR will 
be labeled as per their existing labels that are in current use as part of routine clinical 
practice .  NS is labeled as “0.9% Sodium C hloride  Injection USP”  and LR is labeled as 
“Lactated Ringer’ s Injection USP”  as part of routine clinical practice.   Although an IND will 
be sought for this study for the purposes of  EFIC, since only FDA -approved study fluids that 
are used as part of routine clinical care for pediatric septic shock (as well as other 
indications) will be used for this study, no additional labeling will be applied to bags of 
either NS or LR for the purp oses of this study.  At CHOP, while NS remains the most 
common fluid to treat pediatric septic shock in the ED, 50% of the resuscitation fluids used 
to treat children with septic shock in the pediatric intensive care unit are NS and 50% are 
LR.  Given both  NS and LR are commonly used in routine clinical practice and both are 
FDA -approved, application of study -specific labeling can only contribute to medication 
errors by [CONTACT_589450].  Given the pragmatic nature of the proposed study 
design that is required to expand this work to the larger PECARN network, enroll several 
thousand patients, and optimize external validity, it is not practical to employ a dedicated 
study team to guard against medication errors that may ensue by [CONTACT_2359] a non -
standardized label on FDA -approved, hospi[INVESTIGATOR_307] -issued fluids to be used in this study.  
7.1.[ADDRESS_776334] identical dosing recommendations for use as crystalloid fluid 
resuscitation in pediatric septic shock, which is 20 mL/kg of body weight ad ministered as 
rapid IV/IO bolus. Actual doses administered can vary based on clinician preference and/or 
patient clinical condition.  This study will not prescribe a specific dose of either NS or LR to 
be administered; rather, all dosing decisions will rem ain at the discretion of the clinical care 
team  with guidance as per existing ED and PI[INVESTIGATOR_589413] (see Appendix 5) . 
7.1.4 Treatment Compliance and Adherence  
Because study fluids can only be given by [CONTACT_192942] (rather than self -
administered b y the patient and/or LAR), there will be no concerns for patient or 
parent/guardian -related issues with treatment compliance and adherence.  
   31 
Compliance/adherence with use of study fluid consistent with the randomized arm will be 
tracked for every patient as  part of Aim [ADDRESS_776335] 18 sites through the PECARN network and 
will enroll sev eral thousand patients. Therefore, it is not practical to account for details of 
fluid administered (including, for example, lot number and residual volume not 
administered ) beyond that which is collected for clinical purposes.  Because both NS and LR 
are already used in common clinical practice at CHOP , are both FDA -approved, and all 
decisions regarding timing and volume of fluid to be administered will be governed by [CONTACT_589451] (rather than study protocol) , no specific study procedures will be 
established to monitor study fluid accountability.  Rather, administration and disposal of 
residual volumes of both NS and LR will occur as part of routine practice ca rried out at 
CHOP.  No fluid will be specifically supplied for the purposes of this study since all 
decisions regarding timing and volume of fluid will be determined by [CONTACT_589452].  Thus, because all study patients will receive an efficacious fluid (either NS or LR) to 
reverse shock without additional fluid -related costs generated by [CONTACT_4907], 
hospi[INVESTIGATOR_307] -stocked fluid supplies will be utilized for this study without need for additional 
accountability beyond routine practice.  
   [ADDRESS_776336]  a wide  range 
of potential adverse events , including organ dysfunction , hospi[INVESTIGATOR_307] -acquired infections,  and 
death, to occur as part of the routine clinical course.  In addition, because all 
intravenous/intraosseous medications, including crystalloid fluids such as NS and LR, can 
result in intravenous a nd/or intraosseous extravasation with soft tissue infiltrates, we expect  
that intravenous and/or intraosseous extravasation with soft tissue infiltrates will occur as 
part of the routine clinical care for some subjects enrolled in this study.  Since all de cisions 
to administer fluids for a specified indication, timing, and/or volume remain at the discretion 
of the clinical care team, we do not consider intravenous and/or intraosseous extravasation 
with soft tissue infiltrates to be an unexpected  event.   Finally, b ecause of the strong existing 
safety profile of both NS and LR , common clinical use of both fluids to treat septic shock, 
pragmatic study design with limited, targeted data collection, and because there is no 
biologic plausible reason to anticipate that adverse events related to study fluid 
administration  should occur remote from fluid administration itself , we will not plan to 
continuously monitor for clinical adverse events (AEs).  Instead, we will monitor for AEs by 
a chart review that will occur at two time points —1) after the end of the intervention phase 
and 2) at 5-7 days after the intervention phase (or at hospi[INVESTIGATOR_2345], whichever comes 
first)  as shown in Appendix 3.  We will limit the time period for determination of AEs to [ADDRESS_776337].  
8.2 Adverse Event Reporting  
Unanticipated  problems related to the research involving risks to subjects or others that 
occur during the course of this study (including SAEs) will be reported to the IRB in 
accordance wit h CHOP IRB SOP 408: Unanticipated Problems Involving Risks to Subjects. 
AEs that are not serious but that are notable , unanticipated,  and could involve risks to 
subjects will be summarized in narrative or other format and submitted to the IRB at the 
time o f continuing review.  
   [ADDRESS_776338] who has received an 
intervention (drug, biologic, or other intervention)  and is not anticipated to occur as a part of 
the routine clinical  course of septic shock .  Because septic shock is a complex and life -
threatening condition for which we anticipate a wide range of potential medical events, 
including organ dysfunction, hospi[INVESTIGATOR_307] -acquired infections, and death, to occur as part of the 
routi ne clinical course, there are few events that will be unanticipated.  However, t he 
occurrence of an AE does not necessarily have to have a causal relationship with the 
treatment.  An AE can therefore be any unfavorable or unintended sign (including an 
abno rmal laboratory finding, for example), symptom, or disease temporally associated with 
the use of a medicinal product, whether or not considered related to the medicinal product , 
that was not anticipated to occur as part of the routine clinical course of se ptic shock . 
All unanticipated AEs (including serious AEs) will be noted in the study records and on the 
case report form with a full description including the nature, date and time of onset, 
determination of non -serious versus serious, intensity (mild, mod erate, severe), duration, 
causality, and outcome of the event.   AEs that occur within the timeframe noted in Section 
8.[ADDRESS_776339].  
Intensity of AEs will be defined as follows:  
 Mild:  mild event of its type that does not interfere with routine activities  
 Moderate:  moderate event of its type that interferes with routine activities  
 Severe:  severe event of its type that makes it impossible to perform routine activities  
8.4 Definition of  a Serious Adverse Event (SAE)  
As noted above, septic shock is a complex and life -threatening condition that commonly 
causes organ dysfunction, need for invasive medical and surgical therapi[INVESTIGATOR_014] (including, but 
not limited to, mechanical ventilation, renal r eplacement therapy, plasma exchange, 
extracorporeal membrane oxygenation, and cardiopulmonary resuscitation), subsequent 
hospi[INVESTIGATOR_307] -acquired infections, and even death.  Consequently, the development of new or 
progressive organ dysfunction, need for invasive  medical and surgical therapi[INVESTIGATOR_014] (including, 
but not limited to, mechanical ventilation, renal replacement therapy, plasma exchange, 
extracorporeal membrane oxygenation, and cardiopulmonary resuscitation), identification of 
a hospi[INVESTIGATOR_307] -acquired infection, and death are all anticipated to occur as part of routine clinical 
practice for subjects enrolled in this study  (see Table [ADDRESS_776340] of expected and 
possible unexpected adverse events) . 
An SAE will be defined as any unanticipated adverse drug experien ce that results in any of 
the following outcomes:  
 an unanticipated  life-threatening event (at risk of death at the time of the event), or  
 requires prolongation of existing hospi[INVESTIGATOR_059],  or 
 a persistent or significant disabil ity/incapacity.  
   [ADDRESS_776341] and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  
A distinction should be drawn between serious and severe AEs.  A severe AE is a major 
event of its type.  A severe AE does not necessarily need to be considered serious.  For 
example, n ausea which persists for several hours may be considered severe nausea, but 
would not be an SAE.  On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke, but would be an SAE.  
8.4.1 Relationship of SAE to study drug or other intervention  
The relationship of each  SAE to the study intervention will be characterized using one of the 
following terms in accordance with CHOP IRB Guidelines: definitely, probably, possibly, 
unlikely or unrelated.  
8.5 IRB/IEC Notificat ion of SAEs  and Other Unanticipated Problems  
The Investigator will promptly notify the IRB of all on -site unanticipated, serious Adverse 
Events that are related to the research activity. Other unanticipated problems related to the 
research involving risk t o subjects or others will also be reported promptly. Written reports 
will be filed using the eIRB system and in accordance with the timeline below. External 
SAEs that are both unexpected and related to the study intervention will be reported 
promptly after  the investigator receives the report.  
Type of Unanticipated 
Problem  Initial Notification  
(Phone, Email, Fax)  Written Report  
Internal (on -site) SAEs  
that are Life Threatening  24 hours  Within 2 calendar days  
Internal (on -site) SAEs  
All other SAEs  7 day s Within 7 business days  
Unanticipated Problems 
Related to Research  7 days  Within 7 business days  
All other AEs  N/A Brief Summary of important 
AEs may be reported at time 
of continuing review  
 
8.5.1 Reporting procedures  
AEs will only be reported if judged by  [CONTACT_589453].  SAEs will be reported regardless of whether these are judged to be related to 
administration of study fluid .  See “Adverse Event Reporting”  in Appendix 3 for a flow 
diagram outlining the n eed for and timing of reporting of AEs and SAEs . 
   35 
AEs and SAEs to be collected for subjects enrolled in this study are listed in Table 3, along 
with classification as either expected within the study population of pediatric patients with 
septic shock  or une xpected .  All of the events lists in Table 3 could potentially be related to 
the study fluid intervention, though this determination will be made on a case -by-case basis.  
Other unexpected events not listed in Table 3 will not be collected unless the clini cal care 
team and/or the study investigators determine that the event may be related to the study fluid 
intervention.    
Table 3:  Adverse Events To Be Collected  
Event  AE or SAE  Expected in Pediatric Sepsis  
Death1 SAE Expected  
Cardiac arrest requiring CPR  SAE Expected  
Arrhythmia requiring intervention  AE Not Expected  
Vasoactive infusion  SAE  Expected  
Extracorporeal membrane oxygenation 
(ECMO)  SAE  Expected  
Invasive mechanical ventilation  SAE  Expected  
Non-invasive mechanical ventilation  AE Expected  
Dialysis (not pre -existing) 1 SAE  Expected  
Liver dysfunction  SAE  Expected  
Limb necrosis  SAE  Expected  
Brain herniation2 SAE  Not Expected  
Seizure  AE Not Expected  
Pulmonary embolus  SAE  Not Expected  
Deep venous thrombosis  AE Expected  
Central venous line clo t requiring 
pharmacologic therapy2 AE Expected  
Bleeding (not requiring massive 
transfusion protocol)  AE Expected  
Bleeding (requiring massive 
transfusion protocol)  SAE Not Expected  
   36 
Hospi[INVESTIGATOR_307] -acquired infection3 AE Expected  
Pressure ulcer  AE Expected  
IV infiltrate (grade 3 or 4)  AE Expected  
Rash  AE Expected  
Hyperlacatatemia > 4 mmol/L2 AE Expected  
Hyperkalemia >6 mEq/L2 AE Not Expected  
Hypercalcemia (ionized calcium > 
1.35 mEq/L or total calcium > 12 
mEq/L) 2 AE Not Expected  
Hypernatremia >155 mEq/L2 AE Not Expected  
Hyponatremia <128 mEq/L2 AE Not Expected  
Hyperchloremia >110 mEQ/L2 AE Expected  
1Event also included as pre -specified efficacy outcome  
2Event also included as pre -specified adverse outcome  
3Includes central line -associated bloodstream i nfection, urinary tract infection (both 
catheter -associated and non -catheter -associated), ventilator -associated pneumonia, 
ventilator -associated tracheitis, hospi[INVESTIGATOR_307] -acquired viral infection, surgical site infection, and 
C. difficile  colitis)  
 
8.5.2 Follow -up re port 
If an SAE has not resolved at the time of the initial report and new information arises that 
changes the investigator’s assessment of the event, a follow -up report including all relevant 
new or reassessed information (e.g., concomitan t medication, med ical history) will  be 
submitted to the IRB. The investigator is responsible for ensuring that all SAE are followed 
until either resolved or stable.  
8.[ADDRESS_776342]. Scott Weiss , a CHOP co -investigator,  will be the sponsor for the 
IND.  
8.7 Medical Emergencies  
Medical emergencies that might develop during the course of the study  will be diagnosed 
and treated at the discretion of the clinical team .  
   37 
9 STUDY ADMINISTRATION  
9.1 Treatment Assignment Methods  
9.1.1 Randomization  
Prior to enrollment of any subjects , a complete randomization scheme will be completed  
using  a 1:[ADDRESS_776343] a specific fluid selection.  This scenario was borne out in the previously 
published SPLIT fluid trial in which two -thirds of clinicians correctly identified the 
randomized crystalloid patients received (despi[INVESTIGATOR_589392])  based on diverging electroly te 
profiles .32 
9.2 Data Collection and Management  
Data will be managed and store d by [CONTACT_589454] 
(DCC), which has an established working relationship with PECARN (the planned researc h 
network for the subsequent multicenter pragmatic trial).  We will work with the DCC to 
create the electronic case report form (CRF) for this study.  The CRF will be password -
protected with the safeguards noted below to maintain confidentiality for all da ta entered 
into the CRF.   The CRF will be password -protected and entered via CHOP -issued 
computers. There will be a separate master list linking subject PHI and study data and will 
be stored separately from the study data and will only be accessible to the  CHOP study 
team. Locally secured, identifiable information and partially identifiable information will be 
stored locally at CHOP for this pi[INVESTIGATOR_799].   
The Data Coordinating Center has a state -of-the-art computer infrastructure with a dedicated 
server roo m with a fire suppression system, air conditioning, cooling system and separate air 
filtering. The server facility is locked separately from the remainder of the Data 
Coordinating Center and access to the building is monitored by [CONTACT_589455]. The Data Coordinating Center coordinates its network infrastructure and security 
with the Health Sciences Campus (HSC) information systems at the University of Utah. This 
provides the Data Coordinating Center with effective firewall hardware, automati c network 
intrusion detection, and the expertise of dedicated security experts working at the 
University.  
 
Network equipment includes four high -speed switches. User authentication is centralized 
with two Windows [ADDRESS_776344] 128 bit encryption. REDCap, OpenClinica (Web -based clinical studies data 
management system), eRoomTM (Web -based collaborative worksp ace) and other web 
applications use the SSL protocol to transmit data securely over the Internet. Direct access to 
Data Coordinating Center machines is only available while physically located inside the 
Data Coordinating Center offices, or via a VPN client . All network traffic is monitored for 
intrusion attempts, security scans are regularly run against our servers, and IT staff are 
notified of intrusion alerts.  
 
Production servers running mission critical applications are clustered and configured for 
failover events. Servers are backed up with encryption through a dedicated backup server 
that connects across an internal [ADDRESS_776345]. Storage area networking 
(SAN) applications, clusters, and switch -to-switch links are also on a 10 gigab it network. 
Incremental backups occur hourly during the week. Incremental backups also are performed 
nightly with full system backups occurring every week. Tapes are stored in a fireproof safe 
inside the data center facility, and full backups are taken to an off -site commercial storage 
facility. Security is maintained with Windows 2008 user/group domain -level security.  
 
Users at both CHOP and University of Utah will be required to change their passwords 
every 90 days, and workstations  at University of Utah will time out after 5 minutes of 
inactivity. All files are protected at group and user levels; database security is handled in a 
similar manner with group level access to databases, tables, and views in Microsoft SQL 
Server. All portable computers  at Unive rsity of Utah  are whole -disk encrypted.  
  
9.[ADDRESS_776346] obtaining IRB approval. The 
investigator will obtain a data use agreement between the provider (the PI) of the data and 
any recipi[INVESTIGATOR_5772] (including others at CHOP) before sharing a limited dataset ( PHI 
limited to dates and zip codes).  
9.[ADDRESS_776347] (DSMB) will be 
convened made up of  representatives who are independent of the study investigators.  
Before initiation of the clinical study , the sponsor -investigator will arrange a pretrial 
monitoring visit with the IND & IDE Support Program and the Office of Research 
Compliance (ORC) to co nfirm clinical trial readiness.  After enrolling and starting 
administration of the investigational agent to the first subject, the sponsor -investigators will 
contact [CONTACT_196131] a monitoring visit.  Thereafter, ORC will monitor the study at least 
once during the course of the pi[INVESTIGATOR_2268] .  Monitoring activities will be guided by [CONTACT_12212] E6 section 
5.18.  Monitoring of subject data will be initiated at 100% verification of the data recorded. 
This may be amended, and a tapered approach to monitoring may be employed , if conduct 
and documentation of the study reaches a level of reliability that would permit valid 
conclusions based upon a sampling of data  
9.4.[ADDRESS_776348] (DSMB)  
The PRoMPT Bolus – Feasibility study will have a Data Safety Monitoring Board ( DSMB) 
composed of five members from the CHOP/University of Pennsylvania community who 
have no other involvement in any aspect of the proposed study.  Members of the DSMB will 
be invited by [CONTACT_589456].   At least one  member 
will be knowledgeable in medical ethics and at least one member will be a patient advocate.   
The DSMB will have a charter, will approve the protocol prior to implementation, and will 
meet prior to initiation of subject enrollment , after hospi[INVESTIGATOR_307] d ischarge of the first [ADDRESS_776349] both been previously proven as efficacious for fluid 
resuscitation of pediatric septic shock, both NS and LR are currently used in common 
clinical practice for this indication, and because patients will only be considered eligible if 
the clinical care team (usually the attending physici an) deems it safe for the patient to 
receive both NS and  LR, the r isks presented by [CONTACT_589457].  However, because 
there is a prospect of a relative benefit in efficacy and/or safety for one fluid over the other, 
subjects may be randomized t o an arm with relatively inferior efficacy or relatively worse 
safety . 
Several safeguards have been put in place to minimize risk of randomized (rather than 
clinician -prescribed) fluid administration, including:  
a) Because of the FDA noted caution in using la ctate -containing fluids, such as LR, in 
patients <6 months of age, only patients >6 months -old will be eligible for this study.  
b) Any patients for whom clinician judgement deems it unsafe to administer NS or LR 
will be excluded from enrollment, with specifie d exclusions noted (but not limited 
to) clinical suspi[INVESTIGATOR_589414], known hyperkalemia, known 
hypercalcemia, and known fulminant hepatic failure.  
c) Exclusion of patients with known pregnancy, known prisoner status, or known 
allergy to NS or LR.  
In addition, post -marketing risks reported with infusion of either NS, LR, or both fluids are 
listed in Table 4.  All of these risks that have been reported with (but not necessarily 
causally linked to) use of either NS, LR, or both and are all c onsistent with  the risks subjects 
would experience if they received these fluids as part of clinical care.  Therefore, 
participation in this study is unlikely to expose patients to risks beyond that incurred as part 
of routine clinical care.  However, sinc e it is likely that more patients will receive LR than 
otherwise would as part of routine clinical care, there may be a slight increase in risk for the 
study population as a whole than would otherwise be the case as part of routine clinical care.  
Table 4 :  Reported risks associated with infusion of NS and/or LR  
Risk Reported with NS  Reported with LR  
Anaphylaxis/anaphylactoid reaction  X X 
   41 
Angioedema/Laryngeal edema  X X 
Chest pain/chest discomfort  X X 
Bronchospasm   X 
Dyspnea/Respi[INVESTIGATOR_1506]  X X 
Cough X X 
Urticaria or other rash  X X 
Pruritis  X X 
Nausea  X X 
Pyrexia  X X 
Infusion site reaction (erythema, pruritis, 
numbness, pain, edema, extravasation)  X X 
Bradycardia   X 
Tachycardia   X 
Hypotension   X 
Anxiety  X X 
Headache  X X 
Dysgeusia (metalli c taste in mouth)   X 
Paresthesias   X 
Sneezing   X 
Hyperkalemia  Xa X 
Hypervolemia  X X 
Pulmonary edema  X X 
Acid -base disturbance  Xa X 
Hyponatremia   X 
Hyperlactatemia   X 
Hypernatremia  X  
   42 
Hyperchloremia  X  
Hypercalcemia   X 
Acute kidney injury  Xa X 
Infection  Xa X 
Coagulopathy  X X 
Venothromboembolism  X Xb 
Cerebral edema  X Xb 
 aRisk reported in patients receiving both NS and LR but may be more common with NS  
bRisk reported in patients receiving both NS and LR but may be more common with LR  
The othe r major r isk to subjects enrolled in this study is  breach of patient confidentiality, 
which is itself limited by [CONTACT_589458] 8 .3. 
9.4.4 Potential Benefits of Trial Participation  
Because fluid resuscitation with either NS or LR may offer  relative superior efficacy and/or 
safety, there is a prospect of direct benefit to subjects from trial participation.  
Additionally, indirect benefits to society are clear  because this pi[INVESTIGATOR_589415] 
a larger pragmatic comparative effectiveness study to meet the needs of clinicians making 
treatment decisions about fluid resuscitation for pediatric patients with suspected septic 
shock.  By [CONTACT_589459], 
society (and future patien ts) may benefit from a reduction in sepsis -associated morbidity and 
mortality.  
9.4.[ADDRESS_776350] on the overall risk -benefit  balance to patient to participation in this trial beyond that 
which would  be incurred as part of ordinary routine clinical practice.  Nonetheless, because 
subjects enrolled in this study will re ceive type of fluid determined by [CONTACT_589460] -prescribed (as in usual practice) and there is a potential for a relative benefit in 
efficacy and/or safety for one fluid over the other, the risks incurred by [CONTACT_589461] m ay be slightly higher than in clinical practice.  However, this small potential for risk 
for subjects randomized to a relatively inferior fluid is balanced by [CONTACT_589462] a relatively superior fluid with all su bjects having an 
equal chance of randomization to either arm.  The primary benefit of this trial for patients is 
that each patient has a random chance to be exposed to a potentially more effective fluid 
resuscitation strategy. Given the lack of definitive data indicating which fluid is more 
effective and, thus equipoise, it cannot be known before the study which fluid arm may or 
   [ADDRESS_776351] to be 
considered for eligibility of enrollment into this study.  A member of the stu dy team —
including ED attendings and fellows included and trained as study co -investigators —will 
ensure subjects meet all eligibility criteria prior to study enrollment.  After eligibility is 
confirmed and, in the rare cases were sufficient time is availabl e for prospective informed 
consent, a member of the study team —including ED attendings and fellows included and 
trained as study co -investigators —will seek informed consent.  For most cases, however, we 
anticipate that conditions will not permit sufficient  time for prospective informed consent 
and we will proceed with enrollment under Exception From Informed Consent (EFIC, see 
Section 9.6.3) for which a member of the clinical care team, under the supervision of the 
attending physician of record or his/her d esignee,  will be responsible for obtaining an “opt -
out” from the LAR when possible (see Section 9.6.3 for further details of “opt -out” plan).    
Study fliers ( approved under CHOP IRB study 17 -013950 ) will be posted in the CHOP ED  
to further inform potential  subjects and LARs of this study.  
Based on internal data from CHOP  and published estimates ,53 we anticipate  189-290 eligible 
patients per 100,000 ED visits.  With approximately 20,000  visits over 4 months  to the 
CHOP  ED, we anticipate sufficient subj ects to achieve the study goals with enrollment over 
4 months.  
9.6 Informed Consent/Assent  and HIPAA Authorization  
Subjects will be enrolled using a combination of written informed consent and HIPAA 
Authorization, if feasible, or Exception From Informed Consent (EFIC) under specified 
conditions  (see below) . 
We seek a waiver of assent for all subjects (see below).  
9.6.1 Informe d Consent and HIPAA Authorization  
For patients who meet inclusion criteria and in the rare scenario where sufficient time is 
available to properly and ethically seek prospective informed consent without endangering 
the patient, the p arents or legal guardia ns (i.e., LARs)  will be ap proached for study 
enrollment .  A trained member of the study team —including ED attendings and fellows 
included and trained as study co -investigators —will engage them in a discussion regarding  
reasons for the study, the study proc edures, and the r isks and benefits and answer all 
   [ADDRESS_776352] of the 
study and answer questions during the consent process .  Due to anticipated critical nature of 
the patients’ con dition in septic shock, this discussion may take place at the patient’s bedside 
or in an alternative location (e.g., family conference room) at the parent/guardian’s option 
and the consenter’s discretion.  Regardless of the where this discussion takes plac e, all 
reasonable safeguards to ensure patient privacy will be taken.   If it is necessary for a study 
team member to discuss the study with the LAR via phone (e.g., LAR cannot be physically 
present but time permits for prospective informed consent), then w ritten informed consent 
will still be obtained by [CONTACT_589463] 
a written signature.  
 
For patients who meet inclusion criteria and in the rare scenario where sufficient time is 
available to properly and ethically seek prospective informed consent without endangering 
the patient, we will also obtain written permission for HIPAA Authorization on the 
combined consent -HIPAA authorization form.   
 
We will provide a copy of the combined consent -HIPAA authorizat ion document  to the 
parent/guardian and will write a note in the patient’s medical record documenting the 
informed consent discussion.  
 
If the LAR consents to participate in the study, the LAR will be notified that PHI will be 
retained indefinitely in a co ded fashion with all safeguards in place to maintain 
confidentiality as described in Section 8.3.  
 
9.6.2 Waiver  of Assent  
We are seeking a waiver assent for all patients due to the critical nature of the patients' 
illness in septic shock, often with altered ment al status and neurologic dysfunction from a 
combination of sepsis encephalopathy, shock, hypoxemia, hypercarbia, and/or hyperthermia, 
which will make them unable to participate in a meaningful way.  However, any patients 
who are capable and willing to part icipate in the prospective informed consent discussion (in 
rare scenarios where it is appropriate) will be involved and engaged in this process.  
 
9.6.3 Exception From Informed Consent (EFIC)  
Enrollment of subjects under Exception from Informed Consent (EFIC) req uires the 
following conditions to be present:  
1) Subjects are in a life-threatening situation , available treatments are unproven or 
unsatisfactory , and the collection of valid scientific evidence is necessary  to 
determine the safety and effectiveness of a the rapy 
2) Obtaining prospective informed consent is not feasibl e 
3) Subjects may benefit from the research  
4) Research could not be carried out without an EFIC  
   45 
The specific elements of our study that meet each of these conditions are:  
1) Septic shock is a life -threaten ing medical emergency requiring immediate therapy, 
analogous to myocardial infarction, stroke, or trauma 12.  There are currently no data 
proving the most effective  crystalloid fluid to use for initial, immediate resuscitation 
of children (or adults) with septic shock and existing guidelines are silent  as to which  
crystalloid  fluid  to use as first -line therapy  (with both NS and LR currently 
considered to be equivalent options) .  Prior observational studies in adults and 
pediatric patients have not been able  to determine the comparative safety and 
effectiveness of different available crystalloid fluids to use for resuscitation in septic 
shock, leading to multiple calls for prospective randomized trials to provide the 
necessary evidence to determine comparativ e effectiveness.  
 
2) The current ACCM guidelines to treat hemodynamic shock in pediatric sepsis 
recommend crystalloid fluid resuscitation within [ADDRESS_776353] instances, this exceedingly short time window is too sho rt for a 
proper discussion of prospective informed consent , including sufficient opportunity 
to explain study procedures, discuss  risks/benefits , and answer all  questions, to be 
feasible.  Expanding the therapeutic window beyond 15 minutes would result in 
either 1) delay of fluid resuscitation which would place patients at risk of life -
threatening complications of untreated septic shock, including cardiac arrest and 
death and/or 2)  administration of a large volume of pre -study, non -randomized fluids 
that wi ll prevent the necessary clinically important separation between study arms to 
determine comparative effectiveness of NS versus LR resuscitation.  Our data from 
CHOP and two additional published studies demonstrate that 25 -55% of deaths due 
to pediatric se ptic shock occur within [ADDRESS_776354] and death.  Finally , our data from a survey conducted in the CHOP ED, 
supports that parents/guardians would pr efer not to be approached for informed 
consent in the initial critical period of their child’s emergency care.  Therefore, in 
most instances, obtaining informed consent will not be feasible.  
In rare circumstances, fluid resuscitation may be necessarily del ayed such as with 
parental or clinician initial preference to avoid or limit fluid resuscitation (e.g., 
concern for concurrent heart failure for which large -volume, rapid fluid resuscitation 
may not be in the best interest of the patient) or with delayed I V/IO access.  In these 
rare circumstances when the therapeutic window is extended beyond 15 minutes 
from recognition of septic shock, there may be an opportunity to seek prospective 
informed consent . 
   46 
3) Because fluid resuscitation with either NS or LR may off er relative superior efficacy 
and/or safety, there is a prospect of direct benefit to subjects from trial participation.  
 
4) Because informed consent is not feasible (as noted above), this study could not be 
carried out without EFIC.  Moreover, alternative st udy designs, such as observational 
studies have already proven insufficient to determine comparative effectiveness of 
NS versus LR.  Finally, the study proposed does not meet the human subjects 
research obligations needed to obtain a waiver of informed consent. 
As required by [CONTACT_589464], if the LAR is immediately and physically present during the [ADDRESS_776355] seek to inform of study 
enrollment and the option to withdraw from continued participation: (a) the subject, (b) then 
the subject's legally authorized representati ve if the subject remains incapacitated, and (c) 
then the subject's family if the LAR is unavailable, to comply with the EFIC requirements.  
Given the short therapeutic time window of [ADDRESS_776356] seek 
“opt-out” from the a) potential subject, b) then the subject’s LAR if the subject remains 
incapac itated or age <8 years, and c) then the subject’s family if the LAR is not available.   
The ED staff will be provided with recommended “opt -out” language to ensure a reasonably 
consistent approach for pre -enrollment study opt -out.  Recommended language will  include 
that a) participation is voluntary, b) subjects do not have to agree to participation to continue 
to receive care at CHOP, and c) that subjects can withdraw without penalty or loss of 
benefits to which the subject is otherwise entitled.  However, if the subject is incapacitated 
or <[ADDRESS_776357] study enrollment and provided the opportunity to 
continue or withdraw from further study participation.  To facilitate this discussion, we will 
provide the LAR with a “Post -Enrollment Opt -Out Information Sheet”  which will 
summarize the detai ls of the study, including that the subject was enrolled and treated 
without their consent (as there was no time to obtain it), that the IRB has approved an 
excpetion from informed  consent for the study, and what the procedures for continued 
participation  will be required (i.e., possibly additional study fluid and medical record 
review).  In addition, the “Post -Enrollment Opt -Out Information Sheet” will disclose that 
continued participation is voluntary, not necessary  to continue to receive care at CHOP,  and 
that subjects can withdraw without penalty or loss of benefits to which the subject is 
   [ADDRESS_776358] a study team member sign  the for m if the discussion 
occurs over the phone .  We acknowledge that the LAR’s signature [CONTACT_589470], as these patients would have been enrolled under EFIC.  
However, because of concerns raised by [CONTACT_589465] a possible future 
multicenter trial and our own ethical interests, we feel it is important to document that the 
study indeed discussed the details of the study with the subject/LAR and provided an 
opportunity to opt -out/withdraw by [CONTACT_589466] R to sign that this discussion took place.  
Whether the subject/LAR chooses to continue in the study post -enrollment or not, we will  
document their decision on the  “Post -Enrollment Opt -Out Information Sheet” to 
acknowledge this discussion.  
For subjects enr olled via EFIC, if the subject's LAR or family member could not be informed of the 
subject's participation prior to the subject's  death , they will be informed after the subject's death . 
Our full proposal for executing the elements  of EFIC , including commun ity consultation, 
public disclosure, and submission of an investigational new drug application to the Federal 
Drug Authority (FDA), have been separately described in detail under a separate applicate to 
the CHOP IRB (IRB  # 17-013950 ).  Because of the chall enges of EFIC, particularly in a 
pediatric population, we have ensured  that the study team includes individuals with prior 
experience in this area.  [CONTACT_589471] is a recognized expert in human subjects regulations 
related to clinical trials and has expe rience with EFIC through a prior pediatric trial in 
PECARN.[ADDRESS_776359] legally authorized represe ntative and/or family members when 
prospective informed conse nt cannot be obtained will be documented and this information 
will be made available to the IRB at the time of continuing review .  In addition, all IRB - 
approved materials used for p ublic disclos ure will be submitted to the IND and Public 
Docket 95S -0158, as required.  In addition, we will also submit the materials used to 
disclose the study results following completion of the clinical investigation.  
9.6.[ADDRESS_776360] benefit .  For non -English speaking parents/guardians (LARs), an interpreter will 
assist in th e prospective informed consent discussion (if time permits as describ ed above in 
Section 8.6.1)  using the standardized short -form consent form process .  Informed consent 
will be documented using the CHOP standard short -form consent document in the 
appropri ate native language and on a Study Summary Document written in English.  When 
an in -person interpreter is available, the interpreter will be in the same room with the 
   [ADDRESS_776361] as witness to sign the witness/interpreter section of the Study  
Summary Document if the LAR agrees to prospective informed consent . 
If a non -English speaking subject meets criteria for enrollment via EFIC  an interpreter fluent 
in both English and the native language of the subject  (parent/guardian) will assist in the 
pre- and post -enrollment opt -out discussion.  The pre -enrollment opt -out discussion will 
take place as soon as it is possible for a member of ED care team to identify an appropriate 
translator (e.g., in -person or via phone) and proceed with the opt -out dis cussion, just as it 
would occur for English speakers.  However, just as if an English -speaking  subject is 
incapacitated or <[ADDRESS_776362] equal 
access to the opportunity to participate —and potentially benefit from enrollment —in this 
study (as mandated by [CONTACT_589467] t for “justice” under the Belmont Report).  Given the 
short therapeutic time window of [ADDRESS_776363]  (parent/guardian) will assist in the post -enrollment opt -out 
discussion and help to interpret the “Post -Enrollment Opt -Out Form”.  When an in -person 
interpreter is available, the interpreter will be in the same room with the investigators and 
may act as witness to sign the witness/interpreter section of the “Post -Enrollment Opt -Out 
Form”.  In the case that an in -person interpreter is not available, a phone interpreter who is 
fluent in both English and the native language of the patient (pa rent/guardian) will be 
utilize d and a separate third -party witness to the phone conversation will sign  the “Post -
Enrollment Opt -Out Form”  as the witness .  
The interpreter/witness will not be part of the study team or otherwise involved with the 
study.   If a phone interpreter is utilized for prospective informed consent, we will ask that 
the interpreter email the investigators a statement attesting to the LAR's understanding of the 
study and consent to participate.  if a phone interpreter is used in the post -enrollment opt -out 
discussion, then a separate third -party witness may sign the "Post -Enrollment Opt -Out 
Form" to attest that the discussion took place with an appropriate interpreter.  
9.7 Payment to Subjects/Families  
No payment, reimbursement, gifts, or compensation of any kind will be provided to 
subjects/families for participation in this study.  
 
  
   49 
10 PUBLICATION  
This pi[INVESTIGATOR_589416], but rather to assess feasibility 
for impleme ntation of a subsequent large multicenter pragmatic randomized trial.  However, 
should the decision be made to disseminate the results of our pi[INVESTIGATOR_799], we will only 
present and/or publish de -identified aggregate data following appropriate peer review.   
   50 
11 REFERENCES  
1. Hartman ME, Linde -Zwirble WT, Angus DC, Watson RS. Trends in the 
Epi[INVESTIGATOR_589417]. Pediatr Crit Care Med. 2013;14(7):[ADDRESS_776364] -2015 priorities: an updated systematic 
analysis. Lancet. 2015;385(9966):430 -440. 
3. Akcan Arikan A, Williams EA, Graf JM, Kennedy CE, Patel B, Cruz AT. 
Resuscitation Bundle in Pediatric Shock Dec reases Acute Kidney Injury and 
Improves Outcomes. J Pediatr. 2015;167(6):1301 -1305 e1301.  
4. Balamuth F, Alpern ER, Grundmeier RW, et al. Comparison of Two Sepsis 
Recognition Methods in a Pediatric Emergency Department. Acad Emerg Med. 
2015;22(11):1298 -1306. 
5. Cruz AT, Perry AM, Williams EA, Graf JM, Wuestner ER, Patel B. Implementation 
of goal -directed therapy for children with suspected sepsis in the emergency 
department. Pediatrics. 2011;127(3):e758 -766. 
6. Larsen GY, Mecham N, Greenberg R. An emergency  department septic shock 
protocol and care guideline for children initiated at triage. Pediatrics. 
2011;127(6):e1585 -1592.  
7. Paul R, Melendez E, Stack A, Capraro A, Monuteaux M, Neuman MI. Improving 
adherence to PALS septic shock guidelines. Pediatrics. 2014;133(5):e1358 -1366.  
8. Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med. 2013;369(13):1243 -
1251.  
9. Finfer S, Liu B, Taylor C, et al. Resuscitation fluid use in critically ill adults: an 
international cross -sectional study in 391 intensive care  units. Crit Care. 
2010;14(5):R185.  
10. Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for 
hemodynamic support of pediatric and neonatal septic shock: 2007 update from the 
American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666 -688. 
11. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international 
guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 
2013;41(2):580 -637. 
12. Rhodes A, Evans LE, Alhazzani W, et al. Surviv ing Sepsis Campaign: International 
Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017.  
13. Boulain T, Boisrame -Helms J, Ehrmann S, et al. Volume expansion in the first 4 
days of shock: a prospective multicentre study in 19 Fren ch intensive care units. 
Intensive Care Med. 2015;41(2):248 -256. 
14. Cecconi M, Hofer C, Teboul JL, et al. Fluid challenges in intensive care: the 
FENICE study: A global inception cohort study. Intensive Care Med. 
2015;41(9):1529 -1537.  
15. Long E, Babl F, Dalziel S, et al. Fluid resuscitation for paediatric sepsis: A survey of 
senior emergency physicians in Australia and New Zealand. Emerg Med Australas. 
2015;27(3):245 -250. 
   51 
16. Raghunathan K, Shaw A, Nathanson B, et al. Association between the choice of IV 
crystalloid and in -hospi[INVESTIGATOR_589418]*. Crit 
Care Med. 2014;42(7):1585 -1591.  
17. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a 
chloride -liberal vs chloride -restrictive intravenous flu id administration strategy and 
kidney injury in critically ill adults. JAMA. 2012;308(15):[ADDRESS_776365] Choice for Crystalloid Resuscitation 
Fluids. Crit Care Med. 2016;44(8):1541 -1544.  
19. Young P. Saline Is th e Solution for Crystalloid Resuscitation. Crit Care Med. 
2016;44(8):1538 -1540.  
20. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 
2011;13(2):217 -224. 
21. Tosh G, Soares -Weiser K, Adams CE. Pragmatic vs explanatory trials: th e 
pragmascope tool to help measure differences in protocols of mental health 
randomized controlled trials. Dialogues Clin Neurosci. 2011;13(2):209 -215. 
22. Cook D. Is albumin safe? N Engl J Med. 2004;350(22):2294 -2296.  
23. Kellum JA, Shaw AD. Assessing Tox icity of Intravenous Crystalloids in Critically 
Ill Patients. JAMA. 2015;314(16):1695 -1697.  
24. Karakala N, Raghunathan K, Shaw AD. Intravenous fluids in sepsis: what to use and 
what to avoid. Curr Opin Crit Care. 2013;19(6):537 -543. 
25. Santi M, Lava SA, Camozzi P, et al. The great fluid debate: saline or so -called 
"balanced" salt solutions? Ital J Pediatr. 2015;41:47.  
26. Wilcox CS. Regulation of renal blood flow by [CONTACT_589468]. J Clin Invest. 
1983;71(3):726 -735. 
27. Kellum JA, Song M, Li J. Lactic an d hydrochloric acids induce different patterns of 
inflammatory response in LPS -stimulated RAW 264.7 cells. Am J Physiol Regul 
Integr Comp Physiol. 2004;286(4):R686 -692. 
28. Zhou F, Peng ZY, Bishop JV, Cove ME, Singbartl K, Kellum JA. Effects of fluid 
resus citation with 0.9% saline versus a balanced electrolyte solution on acute kidney 
injury in a rat model of sepsis*. Crit Care Med. 2014;42(4):e270 -278. 
29. Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double -
blind crossover study on the effects of 2 -L infusions of 0.9% saline and plasma -
lyte(R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy 
volunteers. Ann Surg. 2012;256(1):18 -24. 
30. McCluskey SA, Karkouti K, Wijeysundera D, Minkovich L, Tait G, Beatt ie WS. 
Hyperchloremia after noncardiac surgery is independently associated with increased 
morbidity and mortality: a propensity -matched cohort study. Anesth Analg. 
2013;117(2):[ADDRESS_776366] of a Buffered Crystalloid Solution vs 
Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The 
SPLIT Randomized Clinical Trial. JAMA. 2015;314(16):1701 -1710.  
   52 
33. Annane D, Siami S, Jaber S, et al. Effects of fluid resuscitation with colloids vs 
crystalloids on mortality in critically ill patients presenting with hypovolemic shock: 
the CRISTAL randomized trial. JAMA. 2013;310(17):1809 -1817.  
34. Rochwerg B, Alhaz zani W, Sindi A, et al. Fluid resuscitation in sepsis: a systematic 
review and network meta -analysis. Ann Intern Med. 2014;161(5):347 -355. 
35. Young JB, Utter GH, Schermer CR, et al. Saline versus Plasma -Lyte A in initial 
resuscitation of trauma patients: a randomized trial. Ann Surg. 2014;259(2):255 -262. 
36. Shaw AD, Bagshaw SM, Goldstein SL, et al. Major complications, mortality, and 
resource utilization after open abdominal surgery: 0.9% saline compared to Plasma -
Lyte. Ann Surg. 2012;255(5):821 -829. 
37. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric 
septic shock. JAMA. 1991;266(9):1242 -1245.  
38. Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a 
randomized double -blind comparison of [ADDRESS_776367] Dis. 2001;32(2):204 -213. 
39. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African 
children with severe infection. N Engl J Med. 2011;364(26):2483 -2495.  
40. Emrath e, Travers C, C. M, Fortenberry JD, Hebbar KB. Resuscitation with balanced 
fluids is associated with improved survival in pediatric severe sepsis (abstract). Crit 
Care Med. 2015;43(12 (Suppl)):A1047.  
41. Weiss SL, Keele L, Balamuth F, et al. Crystalloid Fluid Choice and Clini cal 
Outcomes in Pediatric Sepsis: A Matched Retrospective Cohort Study. J Pediatr. 
2017.  
42. Baskett TF. William O'Shaughnessy, Thomas Latta and the origins of intravenous 
saline. Resuscitation. 2002;55(3):[ADDRESS_776368] ory of 0.9% saline. Clin Nutr. 
2008;27(2):179 -188. 
44. Ringer S. A further Contribution regarding the influence of the different Constituents 
of the Blood on the Contraction of the Heart. J Physiol. 1883;4(1):29 -42 23.  
45. Doberer D, Funk GC, Kirchner K, S chneeweiss B. A critique of Stewart's approach: 
the chemical mechanism of dilutional acidosis. Intensive Care Med. 
2009;35(12):2173 -2180.  
46. Reddi BA. Why is saline so acidic (and does it really matter?). Int J Med Sci. 
2013;10(6):747 -750. 
47. Semler MW, Wanderer JP, Ehrenfeld JM, et al. Balanced Crystalloids versus Saline 
in the Intensive Care Unit: The SALT Randomized Trial. Am J Respir Crit Care 
Med. 2016.  
48. Balamuth F, Alpern ER, Abbadessa MK, et al. Improving Recognition of Pediatric 
Severe Sepsis i n the Emergency Department: Contributions of a Vital Sign -Based 
Electronic Alert and Bedside Clinician Identification. Ann Emerg Med. 2017.  
49. Washburne JF, Chauhan SP, Magann EF, Rhodes PG, Naef RW, 3rd, Morrison JC. 
Neonatal electrolyte response to amni oinfusion with lactated Ringer's solution vs. 
normal saline. A prospective study. J Reprod Med. 1996;41(10):741 -744. 
   53 
50. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus 
conference: definitions for sepsis and organ dysfunction in  pediatrics. Pediatr Crit 
Care Med. 2005;6(1):[ADDRESS_776369] DV, Webb NJ, Lennon R. Recent developments 
in the detection and management of acute kidney injury. Arch Dis Child. 
2017;102(1):91 -96. 
52. O'Malley CM, Frumento RJ, Hardy  MA, et al. A randomized, double -blind 
comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation. 
Anesth Analg. 2005;100(5):1518 -1524, table of contents.  
53. Singhal S, Allen MW, McAnnally JR, Smith KS, Donnelly JP, Wang HE. Natio nal 
estimates of emergency department visits for pediatric severe sepsis in the United 
States. PeerJ. 2013;1:e79.  
54. Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs diazepam for pediatric 
status epi[INVESTIGATOR_7397]: a randomized clinical trial. JAMA. 2014; 311(16):1652 -1660.  
 
  
   54 
APPENDIX  
Appendix 1:  FDA package insert for NS  
Appendix 2:  FDA package insert for LR  
Appendix 3:  Timing of adverse event collection  
Appendix 4:  Decision -tree for adverse event reporting  
Appendix 5:  Fluid Management Algorithm  
 